<SEC-DOCUMENT>0001193125-15-251273.txt : 20150713
<SEC-HEADER>0001193125-15-251273.hdr.sgml : 20150713
<ACCEPTANCE-DATETIME>20150713163257
ACCESSION NUMBER:		0001193125-15-251273
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150713
FILED AS OF DATE:		20150713
DATE AS OF CHANGE:		20150713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15985780

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d28048d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 13&nbsp;July 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">423 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ian Phillips</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pre-clinical studies suggest Anisina may improve</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>chemotherapy effectiveness in childhood cancer.</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential to improve effectiveness of chemotherapy</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May reduce the risk of life-long side-effects associated with
childhood chemotherapy.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>New York, USA 13 July 2015</B>: US-
Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the
effectiveness of chemotherapy in children and reduce life-long side-effects.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">The study results were presented by Dr Timothy Cripe from the Nationwide Children&#146;s Hospital Research Institute, at the Eighth Annual
Cancer Molecular Therapeutics Research Association (CMTRA) meeting in Boston, USA. The results demonstrated that Anisina significantly improved the efficacy of standard of care microtubule targeting compound, vincristine, in an animal model of
neuroblastoma.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Neuroblastoma is a cancer that is most frequently
observed in the young with more than 90% of diagnoses occurring in children under 5 years of age. It is considered to be the most common solid tumour in children outside the brain. Although childhood cancers such as neuroblastoma are relatively rare
compared to adult cancers, the potential years of life lost are substantial making it imperative that new clinical strategies are developed to treat this disease.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">The importance of this study, from a clinical perspective, is that it shows we can dose animals with a proprietary formulation of Anisina
in combination with the standard of care and recapitulate in an animal model of neuroblastoma the same effect as observed in the test tube.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to Dr Justine Stehn, Novogen Anti-Tropomyosin Program Director, this represents an important milestone in the
development of Anisina as a combination therapy for the treatment of neuroblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study was done as part of the Children&#146;s Oncology Drug
Alliance (CODA) involving Australian charity, The Kids&#146; Cancer Project (Sydney), The University of New South Wales (Sydney), The Nationwide Children&#146;s Hospital (Columbus, Ohio), and Novogen. The objective of this study was to evaluate the
effectiveness of Anisina either alone or in combination with vincristine, in a mouse model of human neuroblastoma (CHLA20). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_down.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_up.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Animals with tumors were treated with i) no drug (control), ii) Anisina alone (150mg/kg), iii) vincristine
alone (0.5mg/kg) or iv) Anisina (150mg/kg) + vincristine (0.5mg/kg). Consistent with existing data, Novogen was able to show that Anisina on its own was effective in reducing tumor growth by about 35%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Timothy Cripe, principal investigator, Nationwide Children&#146;s Hospital said more importantly, when used in combination, the Anisina/vincristine
treatment not only reduced tumor growth but also made tumors &#147;regress&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Of the five animals in the combinatorial Anisina/vincristine
treatment group three (60%) reached a complete response- meaning that their tumors were deemed to be too small to be measured, with one animal showing a &#145;maintained complete response&#146; meaning that the tumor had disappeared for more than 60
days after treatment had stopped,&#148; Dr Cripe said. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;What is exciting about this novel drug technology is that Anisina has the potential to
improve the effectiveness of the current standard of care chemotherapeutic, vincristine. What this means from a clinical perspective is that chemotherapy may be more effective in treating patients. In some cases doses of vincristine used in the
clinic could be lowered thereby minimizing the risk of leaving children with side-effects that have life-long consequences.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Stehn said the
outcome of this study was encouraging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Studies are now underway to validate the combinatorial effect of Anisina with a microtubule targeting
compound in an animal model of adult cancer with the objective still being to have first-in-man studies commencing by mid-2016 once we have completed the standard battery of toxicology studies that are requisite for any experimental drug prior to
entering the clinic&#148;, Dr Stehn said. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anisina </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is a small molecule which belongs to a family of compounds termed the anti-tropomyosins or ATMs. Anisina has been designed to inhibit a protein known
as Tpm3.1. Tpm3.1 is a structural protein and is a core component of the skeleton, or cytoskeleton of a cancer cell. By binding to Tpm3.1, Anisina impacts the function of this structural protein causing the collapse of the cytoskeleton which results
in the death of the cancer cell. Anisina has been shown to be effective against a broad range of cancer types. At Novogen we are focused on the clinical development of Anisina for the treatment of both adult (melanoma and prostate) and pediatric
(neuroblastoma) cancers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CODA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CODA&#146;s
mission is to accelerate development of innovative new therapeutic approaches to the treatment of childhood cancers and to take account of the fact that childhood cancers are different to adult cancers and that the lifelong consequences of cancer
drug side-effects can be far more devastating in a child than in an adult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CODA unites the research and resources of five organizations in Australia and
the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Australian members are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The charity, <B>The Kids&#146; Cancer Project</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The originator of the anti-tropomyosin technology, the <B>University of New South Wales</B> and its commercial arm, <B>New</B><B> </B><B>South Innovations</B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Biotechnology company, <B>Novogen Limited</B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_down.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_up.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The US member is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Nationwide Children&#146;s Hospital</B>, Columbus, Ohio </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is providing access to both its
anti-tropomyosin and super-benzopyran drug technologies. Anisina is being evaluated for its ability to complement the action of standard chemotherapies in childhood cancers. TRXE-009 is being evaluated for its ability to treat brain cancers in
children. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information on CODA is available at <U>www.childrensoncologydrugalliance.org</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug
development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms (the
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that are first-in-class with potential application across a range of degenerative diseases. Given the encouraging data from in vitro and in vivo pre-clinical
Proof-of-Concept studies in the field of Oncology, our immediate focus is to bring our lead Oncology drug candidates Cantrixil, Anisina and Trilexium into the clinic in 2016 pending successful completion of their respective toxicology programs.
Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical indications being pursued, with the ultimate objective of employing both
technologies as a unified approach to therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Kids&#146; Cancer Project </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kids&#146; Cancer Project is an Australian charity dedicated to funding medical research to find a cure for childhood cancer. Thanks to community support
the charity has invested more than $24 million into research and is currently supporting 13 research projects. The independent charity is the largest not-for-profit funder of childhood cancer in Australia. The Kids&#146; Cancer Project was inspired
by one man who promised to find the cure for childhood cancer and make a difference. The Kids&#146; Cancer Project supports research that will increase a child&#146;s chance of survival and that will eradicate or minimise the toxicity of current
treatments children endure. The Kids&#146; Cancer project supports collaborative research that has the greatest chance of clinical success and is excited about the potential that Anisina presents as a potential improvement in chemotherapy treatment.
Visit <U>www.thekidscancerproject.org.au</U> for further information or to donate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.novogen.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Manager </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4109 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_down.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_up.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, but not limited to, Anisina, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to Anisina, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Anisina, that could slow or prevent products coming to market, the uncertainty of
patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Anisina, and other risks detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including
those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g28048img_down.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g28048img_down.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28048img_down.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@+&`P$1``(1`0,1`?_$`,H``0`!!0$!`0$`````
M```````%`@,$!@<(`0D*`0$``@,!`0$`````````````!`4!`P8"!P@0``$#
M`@$%"0D+"08&`P````$``@,$!1$A,1(3!D%18=$RDC-3!W&!D:$B8G(4%4*R
M(W.3TS24-38(L5*"0X-4M%4W\,'")'1%TF.SA'65%D9V$0`"`0("!0D$!P<#
M!0```````0(#!!$Q(5&1$@5!87&!H3(3,P:QP5(T\-$B0G*R->%B@I)#<P>B
M@Q3"(U,D=/_:``P#`0`"$0,1`#\`_N,UTO6R<]W&@&NEZV3GNXT`UTO6R<]W
M&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R
M<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UL
MV?628#.=-V`[N5`:Q?\`:RR6FCJA7WVD@D$62(56NJ,=)N00P&672[RV1I59
M]V+P(E:_LK?SJL$]6.+V+2<2N/;%9J;%MOBNER=E`>7>I08[F69SYB,?,4B-
ME5>F3214UO4=I#10C.H_Y5VZ>PT6X=L.U%3BVA;2VQAR`LUM7/A\94N,6/<C
M"D1LJ4>\W)[/855;U%>ST4E"G'HWGM>CL-'K]JMI;H[2N%]NE3EQ#'5DS(FG
M<T88G1Q-PX`I$:5.'=BD5-:\NKAXUJDY=>C8M!&>T;C^_P!;]:G^<6S!:D:?
M$J?%+:Q[1N/[_6_6I_G$P6I#Q*GQ2VL>T;C^_P!;]:G^<3!:D/$J?%+:Q[1N
M/[_6_6I_G$P6I#Q*GQ2VL>T;C^_UOUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!
M:D/$J?%+:Q[1N/[_`%OUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!:D/$J?%+:S
M*I+_`'R@E$U'>;I32C#RXJZI:3AF!^$P<.`XA>94X26$DFCW3N+BE+?I3G&7
M,V;M0=K6V%'HBHJXKG&,,16L<)2/CZ9T#R>[I*/*SHO+%/F+6CQ_B%+ON-2/
M[RT[5@;S;^V>BE+672@N%&<`'34E2*N('=.KD,$P'.*C2L9KN-,M:/J6@]%>
MG*+UQ>\MFA^TWJW[=;.W/1%+?X6R.R"&KFDHIL=[0J=6"3P$K1*A6AG%X;2U
MH\5X?<:*=6*>J7V7VX&SMJ)G-#VSR.8<H>V5SFD',0YKBTXK26"TK%9#7S]=
M+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C
M0#7S]=+\H_C0&U6::8T;L99#\*_.]V]'PH"5UTO6R<]W&@&NEZV3GNXT`UTO
M6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`
MUTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT!B55=-3AF#GN<_$C&1^
M``.!QP.)*`C'W&M?D]8D8,^#'.;XP=+QH#&U\_72_*/_`.)`-?/UTORC^-`-
M?/UTORC^-`-?/UTORC^-`-?/UTORC^-`?6SS:0^&ESC]8_?[J!9GCK:"MK__
M`)!?&MK*W)>+B&M;4U&0>N3`!K0_,%>4TO#C^%'S*\G-WU5;TL/$ERO6RU3T
MNT53@8G7(-.4/DJ9X6X;^,DK5ERIK/`4Z%U4[JGASMKVLLW#LTI+_B^^/QD=
MGFI:NOAK1ERGUJEJ:5VD.$N"S"\G2\O+JPV,TU_35"^TWB6.M.2E_,FO>:?<
MNPS9BUTE9=*:[;5U+J6,U!H[CM%<9J,QLROC8V"6GFRYQIN?O*1'B=><E"2@
MDWFHI,JKGT1PJUI3N*=2XENK'=G4DXZ.AI[6R'HBZW1:F@EGI(LF+(*FH9CA
MFTCK2YY[I*V2^V\9:61*,8V\=RA]B&I-F9[1N/\`,*[ZY4?.+&['4C=XM7XI
M;6/:-Q_F%=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%
M=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%=]<J/G$W8
MZD/%J_%+:Q[1N/\`,*[ZY4?.)NQU(>+5^*6UCVC<?YA7?7*CYQ8W8ZD/%J?%
M+:R&N5OI;P#[1%14.(PUPK:V"H&3`85%/412@CNK9&<X=QX$.YM:%W\Q'>>O
M%I[4TS0;CV:P5&DZV[4;4VMYQ+6.NU57TX)\V>9D^'[0J5"]G'O0A+JP^FPH
M[GTU1JXNWKW%.7XG)=KQ[30+EV<]H=)BZW[1375@Q(:R\5]%4=S554VJ)[DB
ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ`
MX;HGBF?"1^DI,)V]3N.#V%%<6_%[1_\`L*X@M;<L-J;7:0?M^^'->[M_[.M^
M?6W<AJ6Q$/\`Y-Q_Y*G\TOK!O]\`)]M7?(,?M*MW/VZ;D-2V(.YN4L?$J?S2
M^L]K;`_ALKKW9;-?]I^TC:)L5WMU%=([98IJB)T4-=!'4Q137&OGFTI6QR`.
MT(`,<Q.=<[<\9\.I*E1I1QC)K&7,\,ET:S[%P+_&\[RSHWW$;^LHU:<9[E/'
M0I)-)RDWITZ<(]9Z&V>[&.S_`&=,<D-MN%VJH\,*O:"]W6\2:0]V(*BJ%"QQ
M/YL("JJO$;NMH<DHZHI+]O:=_8>C/3W#\)0I2JU%]ZK.<^O!O=_TG5XI98(V
M0PR2111M#(XXWN:QC6C`-8T$-:T#,`H+TO%YG3QA&$5&*PBEH2T(V6T5%0:>
M7&>8_##/(\^X'G+3/,F4,B7;55+#I,J)VG?;*\'Q.7@WF='>;@SE3NE'GN=C
MS@04!+4=UEJGF,ZQC@W2Q$KBW)GSG$>-`2.NEZV3GNXT`UTO6R<]W&@*A++@
M_P"%DY(]V[\YO"@+*`(`@"`(`@"`(`@"`(`@.;WSM/L%HGEI*5D]WJ87.9)Z
MJZ..DCD;D+#528ZPAV0Z#7`'=4JG:5*BWGA%<^91W?'[.WDZ=-2JU%JT)=;S
MZD<[N':YM!4:3;?26^VL/)=H/K9P-SRYRV'']FI4;*DN^VWL*:MZCO9Z*,84
MUT;S[='8:+<-I+_=<?:%XKZEKL\1J'QP=P00ZN$#]%28TJ<.[%(J:U[>7'G5
M)R6K'!;%H-9KA_E*CT"3@,IRC',O9%-*0!`$`0!`$`0!`$`0!`$`0!`$&9)4
M-YNUL(=;KE6T6!QPIZB6-A]*,.U;N^"O,H0GWDF;J5Q<4/(G.'0VC>+?VJ[4
M4FBVJ-%=(P`#ZU`(93^VI3$<<-]KE'E9T998HM:/'^(4G]O<J+G6#VK`WVU]
MKMGJG,BNE!4VQSL`ZHB>*RE:3DQ<&MCJ&,!W0UV"C3LIKN--;"XM_4=O4:C<
M0E!OE7VE[GV,ZM#-#4PQ5-/+'/3SL;)#-$X/CEC<,6O8YI(+2%#::>#S.@A.
M%2"G3:<'DUD7%@]!`$`0&UV8849)W97X<.&KS>!`2J`(`@"`(`@"`(`@"`(`
M@(NYYX/1?[X("+0!`$`0'PD-SG#^V]G0%HS-')!/=R<:`MZY^(PP;X_RH%F<
M8K*>"*X5[XX(HWR5U4][V1M#WO=/(7.<\#2))5A%MQ2>6".5G"$;FHXQ2;D^
M3G+*R9"R"&VB^P;Q_H)O>KU3\V'3]1"XC\C6_ML\^JV.$"`(`@"`(`@"`(`@
M"`(#[B<",<ASC</=&8A!S<AK=SV0V8O&D;A8[?-([//'`*:IQW_6*;4RD]TE
M;85ZU/N2:7TUE?<<*X;=::]&FY:TL'MC@SGUT[%]GZALCK9<+A;'D'1CE,=?
M3@X'<D$51A^T*DPXA57?2EV?384=SZ0L:B;MJE2F\,GA)>Y]I^B>Q]JEM^R&
MRM"9&3FCV<LU,9&@QB0PV^GC+PQQ):':&.&)7*UIJ=>I+7-O:V_>??>$6TJ'
M"K:ECO;EO3CBN7"*6)..:6G1<"#O'^V4+43\M#S*4!L=G^CR_'?X`M-3O$JA
MD2R\&\("4M/TD_%N_*$!LB`("IN9_HCW[4!2@"`(`@"`(`@"`(#Z`2<`"3O`
M8E!F8<U?;Z>9M/47"@IZA^&A3U%;2P5#\<VA#+*R5V)W@LJ,FL4GAT&N5:C3
MDH5)PC-\CDD]C>)?J0X4U0<",:><@Y<#\"_*#NI'-=)FIY<OPOV'B$*_1\M/
MJ`(#X1CD.4'(0=U`14]HII27,+H2220W`MQ/FG,.X4!&RV6H:?@WQRCOL=N;
MCO)\:`P):.HAY<,@&_H$MYS<6^-`8R`(`@"`(`@"`(`@"`(`@"`(`@/5/9N2
M=C;5B2<'5K1B<<`*VHP`W@%47?GRZ?<=_P`#_3*?\7YF;PHQ;%Z.GGEZ.*1^
M.ZUA(\.&"`D([-5OY>A#FY9TCEX&8[B`D8K+3LP,LCY3NM`T&8][%Q\(0$NQ
MC8VM8QH:QHP:UHP``W`$!4@"`(`@"`(`@"`(`@"`("+N>>#T7^^"`BT`0!`$
M!A/.+W8[Y'@."`H0!#*S.27#Z=6_ZRI_ZSU/AW5T'+U?F)_B?M,->SR$!#;1
M?8-X_P!!-[U>J?FPZ?J(7$?D:W]MGGU6QP@0!`$`0!`$`0!`$`0!`$`0!`=)
MLW:CM!:J>FHYH:&Y4E+%'!"V>-T%0V&)H9&SUBG<W2T&``%S''?Q4.=G3FW*
M+:DSHK/U+?VE.-&2A4I122Q6#P7.O>F3EX[?-DK'04U9M)0W6V12UD5)ZQ1P
MLND4<DL<L@+F1&&JU6$1Q(C<1O+7#AE>K)QHN,FECI>'[";=>N>%VE*-7B4*
MM.+ENXQ6^D\&^3!X:-3-DV=[5>SC:K5ML>V5BJ9Y,-&BJ*QMMK\3[DT5R%)4
ME_`&E:*ME=T/-IR2UX8K:L2SX?ZI]/<3P5G=T93?W7+<E_+/=?8=DLP+J>31
M&EI2@MT<H<-`96D8XCN*OJ=XZBAICBLF;#'05<N:%S1DRR>0!CZ6!7@WF='9
MW'`RS!N^(VEQYSBT>)`25-104QTF:1>1@7N=CDX`,`$!F(`@*FYG^B/?M0%*
M`(`@"`(`@"`Y!VD=MVQ?9A5P6R^"[5UXJ:-M?#;+51LD>*6222**6>KJIJ:D
MA;))"X`:3G>3CAFQFVUA7NH[\-U4\<,6SF>.>K.%<`JJWN_$G<RCO*,%R/0F
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MMEDO\0`#I&QRVBM(!P)UM(9:5SB!U(4RIPN@_+<HO:B#;>N.)T7NW4*=:*Y>
MZ^S1V';-EOQ(;%[0UM%;*^WWBP5]?404D!GCBN%`ZJJ)&Q0QFKI'":-KY7`!
MSX0!CE(4*KPVM3BYQ<912QU/M^LZ:P]:<,O*D:-6%2E5FTEBE*.+T+2M/7@>
MA3D)!R$9".%5YU^)\6`?4`0!`8\M+33#X2&-W#HAKM[E-P*`CY++3NZ-\D1P
MR9I&]\.P/C0$=+9JEF)8Z.0;GE:#O`X:./?0$?)2U,720R-X=$EO.&+?&@+"
M`(`@"`(`@"`(`@+L<$TO1Q2/X6M)'APP"`D([/5OY>KB'G.TCW@S2_*@/7'9
MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+`
ML@CQ:<0YPTW>%^*C%N97!N#,!D`[@&0(`@"`(`@"`(`@"`(`@"`(`@"`("Q/
M3LJ``XN:YN.BX8'#'."#G!0$<^WRMY#FO'#Y)[F7$>-`8KZ>:/*^)X&_AB,O
M",0@+*`(#!?RW>D[\I0%*`(969R2X?3JW_65/_6>I\.ZNA'+U?F)_B?M(JIK
M*2C;I5=53TS<^,\T<?#D#G!QR;P6Q1E+NILTU*U&DL:LHQ7.\#6JO;>PTV(C
MFFK7C)A2PNT"1_S9C$S#N8K;&WJRS6"YRMJ\:L:?=<IOF7O>"-,O.W$]RI9Z
M&FHV4M/4L,<LDLAFG=$3Y36AK61QEPW?*(4BG;*,E*3Q:*B\XS.YI2HTX*,)
M+!MO%X>Q=IHJE%($`0!`$`0!`$`0!`$`0!`$`0!`<D[9_NG2_P#G*/\`AJU3
MN'^>_P`+.7]6_IL/[R_+(\O$`YP#AE&(QP/`K@^;X)GZJ?@.EFF[.ML]=++-
MJMLHF1:Z5\NK9[#HCH1ZQSM6S$XX#`8KC_422N88?![V?H?_``_.<^!W6^V\
M+I)8MO!;D<L<CW$N?/K00!`$`0%3<S_1'OVH"E`$`0!`$`0!`?G#^+G^IML_
M_'VS^/NBZ7A/RC_N/W'P[_(_Z]#_`.:'YIGEM61P(0'T`N<&M!<XYFM!<X]Q
MHQ)60M+P69/4VR.TERAD]6M-4&NBD#9:EHHXB7,<!Y=28L1CO`K7XU*#^T_>
M3:7"N(7,'X5*6ZUF_LK:\#F=K[";Q-HNO-ZH*!N'E14,4MPGRG$C6/\`5:=I
M'`7*7+B,/N1;Z='UD*AZ0N:CWKJK""U13D_<O:=9V0['=C[7>K-43MK[K4P7
M2W3,DK:HQ0B6*KA>QXIJ1L#3HO:#@YS@H=>^KRI22PBMUY?6=%PWTQPRVNJ4
MY*=2HJD>\]&.\N18'Z`BEI8RX,IH&C2.:)F.<[I:2N?<I/-L^PJC1AHC&*70
MBF2DI91A)30/'#$P'PM`**4EDV8E1HS6$HQ:Z"-FL%!)B8Q+3G#]6_2;CZ,F
ME^5>U5FL])$J<.MY=W&+YGH[<2)FV<J&XF">*0;@D#HG>$:;?R+8JT>5$2?#
M*JTTY*73H(J:VUT&.LI9<![I@UC>=&7`=];%.+R9$G;5Z??@\-J[#"S'`YQG
M&Z%Z-'+ARA`$`0&/)24TW20QD_G!NB[-ARFX%`1TEEIW98Y)(N`X2-\!T7>-
M`1\MFJF8ZMT<HX#H.\#LGC0$?+2U$/2PR,X2TX<X8A`6$!=C@FE.$<4CSYK'
M'PG#`("0BL]6\8O#(O2<"</19I(#/BLD0RRRO?P,`8,>Z=(E`2,5#20X:$#"
M1NO&F<=_R\4!E=S`<`R#P(#Z@/4W9I]S+5\97_Q]0J>[\]_3D1WW`OTRGU_F
MD;VHY;A`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`6GPQ2<N-I._A@?","@,9UN
MB>?(<YA./G-S;QR^-`0,U(]LCP"UV#W#>S.(W4!;%-(<^BWNGBQ0%]E(W$:3
MR?*&0``8=TXE`LSQ-M;M%>G[07ZD%PGBIX+O<:>.*G+8`(XJN5C0YT0:]QT1
ME).5=!0HT_"C+#%N*]A\FXE?WDKRM3\22@JDE@M&A2>HTASG2.+WN<]YRE[W
M%SB3G)<XDG%24DM"*AMR>,FVSXLF`@"`(`@"`(`@"`(`@"`(`@"`(`@"`Y)V
MS_=.E_\`.4?\-6J=P_SW^%G+^K?TV']Y?ED>7U<'S<_4_P#`5_3K;?@VUBQ_
M]%1+D/47S,/P>]GZ%_P[^AW?_P!:_)$]S+GCZX$`0!`$!4W,_P!$>_:@*4`0
M!`$`0!`$!YR[9>P>A[4;M3;0P;426*[TEKBM@@FH6W"W5,-/-//"YPBFIZJG
METZAP<07@C#R1AELK/B#M8.E*.]!O'4SB?4WHV'J"YC>TZ[I7$::C@X[T6DV
MURIIZ>?H/,M1^%C;JDE?K+A:*^E:XADEI?)+4R,&.#_5J]M!JW'>TGJR7%K:
M62DGS_6CAI?XYXS3;<ITIT_W,6]DMWWF*.R.W6-P;>;;=Y)6G+[2;-2P$C>9
M"R)CACY[E[_YDJGEM8<PCZ7M;.6%U&JYKXL8KLPT=9L-%:[;;FAM!04=(-^"
MGC8\\)ET3(X]TE:I2G+3)MEE1M+6@O\`L4X12U+WYDDR&>J+HZ>&:ID+7>1!
M')-(<A]S&USEY;4=+T(DJ,JF,::<I89+3[#6J'83:BOT2+:ZDC/ZROD92C#?
MU;BZ?-YB]NO2BL\2)2X3?U<'N;L=<GA^WL-YLW9B^EJ:6LN-U8YU/-%4>K44
M#BUSHGB1K'5$Y:='2;EPCQPS+3.ZWHN,5FN4M+;@3IU(U*U1?9:>$5JTYOZC
MK9RDG?)/A40Z-Z0A@(`@"`L34U-.,)H(I>%[&D]YV&D/"LIM9-GB=*E46%2,
M6NCZ,BYK!028F/6TY\Q^FT?HR`GQA>U6FL])#GPVWEW,8O;[2*FV<J6]!/%*
M-YX=$[_&T^$+8JT>5,B3X967ERC)<^A^]$3-;JZ#++2RAOYS6ZQG.C+@MBG%
MY-$2=M7I]^$L-OL,/=PW1G&Z.\O1H"`(`@*-!F?09COZ(Q\.&*`JPPR#($!]
M0!`$`0!`>INS3[F6KXRO_CZA4]WY[^G(CON!?IE/K_-(WM1RW"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`("IG*'?_(4!`S=++\8_WQ0%M`$!Q?;'L;M^T%;4
M7:SU_L>OJWOFJH)HG5%!45#\KYVACFS4LDKLKL--I)QP"GT+Z5*.Y-;T5EK^
MFPY7B?I>A>U97-M/PJTGBTUC%O7K6/+GT''+IV/[<VW2=%;X+M$T$Z=KJHY7
MX#=]7G]7J">`-*GPOK>>;<7SG,7'IGB]#%Q@JD=<&GV/!G/*VW7"VR&*XT-9
M02`X%E933TSL=X:YC`[O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J"`(`@"`
M(`@"`(`@"`(`@/A(&<@=U`2E%9;O<2!16ZKJ`<NFV%S8OEI`R(>%:Y5:<.\T
MB31L[JX\FG.2Z-&UZ#;*3LXOT[0ZHDH:''W$LSII!W6T['L'.4>5[2B\%BRS
MI\`O9K&HX0Z7B^Q/VGRK[.;_`$XTJ=]%7[S(9C#*[@:RH;&TG])9C>TI9XHQ
M5X!>PTTW"?0\'V_6<OV_['^TO;.ST]HV=V1N5;6LN]+/()334--'`V"K8Z=U
M973T],8FND&5KG'+F4ZTO[2A4=2K-*.Z^?L6DYGCWICC_$[6-M96M25554WC
MA%);LECO2:6QC9+\".WE>^&;;/:K9_9FE.BZ:DM(GVANH9G=&UVC0VR*7#)C
MK96@[A7JOZAMX:*$)2EK?V5[WV(C\-_Q#QBLU+BEQ1MZ?*H8U)]'W8I];/T.
M[-NS79;LIV8@V5V3I98J-DKJNMK*N03W&[7&5K&35]PG:R-CYGMC:UK6M;'&
MQH:T`!<S=W=:]K.M6>EY+D2U(^U\"X#P[T[8+AW#8M4D\7)O&4Y/.4GHQ?,D
MDEH2P-^48N0@"`(`@*FYG^B/?M0%*`(`@*'O9&`7N#0<V.[W!G*`Q75K!R6.
M=OX^2/[R@+#JV4\D-8.`8D=\XCQ(#&=)(\XN>X]_)X,R`H0!`?'M;(PQRM;)
M&1@8Y&MD81O%CP6D=Y$VM*S,-*2W9)..IY&N3['[+5,WK$U@MCI<<2YM.(FN
M.?%T<19$X]UJVJO66A2>!"EPSATY[\J-/>Z/<M!-14E+1021T=+34D8BD`92
MP14[<-!VY$UN*\;TI2^TV]))C2IT8.-*,8K#D27L.-*>LCG'F%DP$`0!`$`0
M!`$`0!8,EB:EIJCIJ>&3A<QNESP`[QKTI263-4Z-*IWXQ?414VS]!)B8C-`[
MS7ZQG-DQ/@(6Q5IK/!D2?#:$NYC%[?:14VSE4W$PS0S#<#M*)_CTV>,+VJT>
M701)\,K)8PE&79^PA:BEJ*5^KJ(GQ.W-(9'#?:X8M<.X5M4E+(@U*52E+=J)
MIEA9-80!`$`.0%QR-&=QR-'=<<`$&*6EY`90'#*TY0X96D;X(R$(.?D"`]3=
MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_`*<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI`
M=%V48A9_XLD\)-=1K?'J,H*="$FI)-;VC/3EI9K%5M]M#.3JI*:C9EP;3T['
M.&._)4:YQP[RV*WI<N+(-3C%Y/NN,%S+WO$Q(]M-I6.TO:1DS>3+3TKFG-D(
M$(SKUX-+##`UKBE\OOX]2^HGZ/M(KF8-K[?35(R8R4SWTTF&[Y#M=&3S5K=M
M'[K:)E+C=6*PK0C+G3P^LVNBV\L%5@)I*B@><,14PET8W_A8#(/"`M,K>HLL
M&6%+C%G4[SE!\Z]ZQ-D94VN[PEC)J"YP.&6(FGJV$'/I0OT\.^%JPG!\J9.4
M[>YC@G"I!\FA]AI]U[+MA[KIF6QQ4,SSB9K5)+;W@[^JB)IMW=C*WPN[B&4F
M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<`
M.&(E2H<2E_4CL**X]'0>+M*S3U37OCA[#G%T[(MN;9I.9:X[K"T$ZVU5,=2<
M!NFGDU%5FWF%2X7UO/-X/G**X]-<7H94U4CK@\>QX/L.>UE#6V^0PU]'5T,H
M)!CJZ>:F?B,XPF8S%2HRC)8Q::*6I2JT9;M:,H2U237M,5>C6$`0!`$`0&?0
MVNXW-Y9;Z*HJW-Y6IC+FLQS:<F2-F/"0O$ZD(+&;21OHV]>X>%"$IM:E[\C<
M*+LYOU1HNJGT=O8<XEE,\P'Q=.',Q[KPHT[VE'1'%LM*7`;VIIJ.$%SO%[%]
M9MM%V:6F+`UU965KMUD>A21'O-ULI'Z04:5]4?=27:6E'T_:Q\Z4IRU+[*][
M[3>;7L=;Z;1=;[%"'##_`#$D&L?W=?5%QR<!4>I7JR[\BYM^%4*?R]%)ZVL>
MV1MT.SU4X#72Q0M'N6XRN`PS`#18/"H[FBTC8U7WVDMO["4BL%$S`RF6<C/I
M.U;.;'@[#OKRYOD),+&C'O8R).*EIH.A@BCPW6L&ESR"[QKRVWF28TJ<.Y%(
MS&$XYSFW^$+![,R.JJ(\-"5X`W"=(>!V(0&8RZRCI(V/]'%A_P`0\2`S&7*G
M=RM.,^<W2'A;B?$@,UDL<H)C>UX&?1..'=&<("M`$`0%3<S_`$1[]J`I0!`$
M!%5G3;N89\V;W/!_>@,1`$`0!`$`0!`4NY#\W1OY7)Y#L_`LK-&)=U]!Q-W*
M=FSG-FSG-P;RL%DN@YAYOI/BR8"`(`@"`(`@"`(`@"`(`@(7:'[/'(Z:+I.7
MN]!P[_FK92[Y`XE\OR=Y?1&CJ4400!`6I>CDZ7,>AZ7,.B\[>X5E9F)=UY]6
M9Y)[4?I4W]2>5_OGV+RQT'F?FJXM,EY75F<#QOOOYO\`C[G47>ROZ3#_`%)S
M_P"S?87[;S-]+S+^EUYFS@7F1^;_`(.YUGK*/D,Z3DCI>ES?K//W^%5+RY.H
M[F/7UGK'L[^YMFZ'HY^AS?2I^D_Y_P"?YV*H[GYB69]"X)^FT\N7++-]NOGQ
M-T6@M0@"`(`@"`(`@"`(`@"`(`@"`(`@"`(#&K/HTWTWD'[/^F_]OYZRL^3K
MR-=7RI=_+[O>ZCPCVJ?:4W]2NE_^Z?9V<]!YN]P+I+3+^EE]W,^2>HO-E\_G
M_7RZO<2?9UR&?</..3]L<H9O.WE&O?\`=_Z2Q].Y+Y#J\P[9=OHS?L?HV_:/
M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/`I*R.?EWGEGR9=1;63`0!`
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_`$5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\`Q'RCB/S#^7S?D]TU9;RO"`(`@`SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0!`$!6S/WO[P@+J`(`
<@).V=.[XIV;TV<K^Y`3J`(`@*FYG^B/?M0'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g28048img_up.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28048img_up.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/@+&`P$1``(1`0,1`?_$`,H``0`!!0$!`0$`````
M```````%`00&!P@#`@D*`0$``@,!`0$`````````````!`4"`P8!!P@0``$#
M`P`%"`,*"0H%!0````$``@,1!`4A,5$2!D%A<9&AT1,'4J(4@;'!(C)RTG,5
M"$)B@K(C,R0T-I+"0U-C@[-TM!94-76U=I0E11<W$0`"`0,!`P<(!@@%!0$`
M`````0(1`P0A,1(%05%AD:$R!G&!L<'1(A,S0K(C%#0U\.%B<J)S%0=2DL)#
M)/&"4W06H__:``P#`0`"$0,1`#\`_N*)-3I.L\IVH"E3M/64`J=IZR@%3M/6
M4`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@
M%3M/64`+BT%SG;K1I+G.W6@#E+B0`$#:2J]AB'$'&'#.,LKMEYFK+Q!$:P6\
MOMD]:@T\*U\4@]-%MC8O3[L70@WN)X&/\R[&O,M7U*II'(^;V'@JW&XV]OW:
M0)+A\5E#4<N[^GF(KS-4B&%<??:2*F]XDQX_A[<YOI]U>MF#9#S7XGNZMM!9
M8MAU>SP>/,!SS71E%><-"D1PK,>]67Z=!57O$&?<^7N6X]"J^MU]!@U_F\OE
M7;^2R5Y>FM:7$[WL!&K=BJ(F4KR`*1&W"'=2157LG(R'6_.4WTOU;",69H"`
M(`@"`(`@"`NK6^O;&036=W<6LHU26\TD+]&US'-)',="\E&,E2231G;N7+4M
M^U*49<Z;1FUAYF\66):)+R'(Q"@W+^W9*ZFSQXO!GKTN*CRQ+,MBIY"UL\=X
ME9TE-3C^TJ]JH^TSC'^<5J_<9E<--"=`=-87#)F`^EX%QX3@/[PJ/+!EMA)>
M<M;/B6&S(M-=,77L?M,YQ_'W"62W1%EXK:1QH(L@U]D^IU#>E'@FO,\J/+&O
M0U<:KHU+6SQGAU_9<49<TO=].AEL4D<[!)!)'/&1420O9+&0=1#XRYO:M#JM
MI91E&:K!IKH=3[0]"`(`@"`(`@,KPI_8W?6O]Z-`2U3M/64`J=IZR@%3M/64
M`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@+
M2[N7P-;NZ7/)`))H*4Y!2NM`13[NX?H,A:-C/BCLTH"WJ=IZR@%3M/64`J=I
MZR@%3M/64`J=IZR@*@FHTG6.4[4!QQQ&U[^),\UK7/<<SDJ-:TN<:WDW(`2K
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M:*2]!>+PVA`$`0!`$`0!`0^2X?P>9!&4Q5E?$BF_-"WQ@-7Q9V;LS:<SEG"[
M<M]R31%R<'#S/Q5J$WSM:]>WM,!R/D_PO=;SK";)8AYT@0W'M=N#R?HKL/DI
MT2!2HY]^/>I)=7H]A19/A3AMYN5EW+4NA[RZI:]I@.2\F>(;?>=B\G8Y)HJ0
MR9TN/G(V4>9X"?RPI,.(6WWTUVE'D>$,ZWKC7+=Q<SK%^M=I@&2X0XLQ`<Z_
MPN2BB::&>*)UU;[:^-:F:/=YR0I4,BQ<[LE7J])19/"N)8GS[-Q1YTMY=<:H
MQDO>"6ES@X:""2"#L(.D%;BO])0O<`3O.T"ORCWH#N#R]^ZKA,S@<'Q%Q/Q5
MEIQF<;995N+PT%O91P17L$=RRWEO[L7DTKVQR`.+(XQ74N;RN-W;=V=FS"*W
M9-5>NS39H?9N`_VPPLW!L9_$<FX_C6XSW+:44E))I.4MYO;K1(Z*X>\B_*GA
MIT4MAP?87=U$!NWN:?/FKG>'X8^T))K=CB?0C:%57>)9M[2=QJ/,M/0?0<#P
M3X7X<U*QB0E<7TKC=Q_Q-KJ2-KQ1QPQLBAC9%%&T,CBB8V.-C1H#6,8`UK0-
M0`HH3U=7M.G5N$4HQ244M$M%U(R7#_N\WUP_,6BYWO,2\=))T)AKWL.\QSFG
M:TD'L6!(+Z/)WD>N7?'XXJ:;-X4=VH"6LLDZZ>8G,W7;A=O-<=W00#H.GEVH
M"3J=IZR@%3M/64!4$T.DZMIVA`4.L])]]`40!`$`0!`$`0!`$`0!`:NSOFKA
ML9/+:8ZVER\\+GQR3,D;;V+9&&A:V8MDDG`<-):W=V$J9;P[DUO2>ZNTH,OQ
M!C6).W8B[LTZ5K2/7JWYEYS7=_YK\47=6V@L<6PU_=[?VB8`_P!M=F5M:<H8
M%)CAV5WJO].@IKWB'B%SY>Y;70JOK=?08-?YO,90DY'*7U[4U+9[F5T?N0[P
MB:.AJDQMPCI&*7F*F]DY.1\^Y.?E;IU;""O!^R7``_HG:`-A!.@<P69H,*.L
M])7@*(`@"`(`@"`(`@"`(`@"`(`@+NSO[['O$EA>75F\&N]:SRP&O/X;FAWN
MKR48R5))-&RW=NVG6U*47T-KT&;8_P`SN++'=;+=PY*,"A9?V['O-/[>'P9J
M\Y<5'EB69;%3R%I9X[Q&SWI*:_:7K5&9WB_."RF?'%F,5+9@T#[JRE]IB;^,
MZWD:R8-KZ+G'F4:>#)*L'7REOC^)+4FHY-MQZ8NJZGKU-FWK6ZMKVVAO+.:.
MXM;A@E@FC.\R2-VIPY1S@Z0=!4)IQ;C+1HZ.W<MWK:NVFI6Y+1GNO#,(`@"`
MRS#`BR)(T.E?3GIN5/14("40!`$`0!`$`0!`$`0!`$!&9+5#TO\`>:@(I`$`
M0!`?+G-;K/?U(#R,XT[K3S50'F9GDZ*#H'?5`C3M]'''D,@YD<;'/O;ISW,8
MUKGN=/(7.<YH!<2=JGP;<57F.7NQC')N427O/DZ2U69X$!$9_P#Y%E_\A/\`
MFE96_FP\OL(?$/P5[^5+T'/:MC@P@"`(`@"`(`@"`(`@"`J"1J)'0:(>D+D>
M'<#EPX9/#XZ\+M<DMK&)^D7$89.#T.6<+MRWW)-><AY&!@Y7XBU;F^=I5ZU1
M]IK_`"?DYPK>![K&3(XF0@T$,XNX!H/]%=M?)3F$@4J&??CWJ2\NGH*/)\)\
M,NINR[EJ70]Y=3U[3]!N#,0_&\'<*6#9FS^Q\.X>V$A;X1D\&P@CW]W>>&;V
M[6E31<M?G\2_<GSS;ZW7UGWC@V*\?A.-93WMS'MQKLK2*52><US#NN%#S\O0
M=16HL'5.CT/E#PR/#?N\WUP_,"U7.]YB38V,EEK)`0$GB?WH_5/]]J`R5`$!
M4:CT?"$`.L])]]`40!`$`0!`$`0!`5#2=0)IKH":=*'M&]ACMYQ?PECKIMCD
M.*>&[&]<0T6=WG,9;W)<30`PRW+9&DD\H"V*S>DMZ,)./D9!N\3X;8N?!OY%
MB%U\DKD4^ILFW/9-:2S0O9-"^WE<R:%[987@Q.H62QES'`[05BDU))[:DIN,
M[3E%IQ<7JM5LYT<2'6>E7R/EH0!`$!&SXNUF)<&NB<:FL9`!)Y2T@MZJ("-E
MPD@J89F/'('M+'=8W@@(^7'W<7RH7D;6C>'JDH"S((-"""-8.@H`@"`(`@"`
M(`@"`(`@"`(`@"`ZF\M/X.QO-+>TYOVN95.7\]G>\!_+(>67UF9VHI<%U%97
M4U/#@D(.IQ;NMZ=YU&H"_BPEP[];)'$-@K([U:-[4!(Q8:UCH9#),=CCN,K\
MUNDCW4!*M:UK0UH#6@4#0``!L`&@("J`(`@"`(`@"`(`@"`(`@(S):H>E_O-
M0$4@"`(`@+%_RW?./OH#Y0!#U;34N1_?KW_.7/\`C/4^'=7D.8O?B9_O/TED
MLS`("(S_`/R++_Y"?\TK*W\V'E]A#XA^"O?RI>@Y[5L<&$`0!`$`0!`$`0!`
M$`0!`$`0&>X?S(XGQ$%O:":VOK.VC;##!>P!SF0L%&1MN(713[K&B@J74"BS
MQ+,W752?,7F'XAXEAP5J,HSM)))26Q+DJJ/M9+YW[P>%X<QMO?\`$F"R#(GW
MT%HZ;#20WGANFCF=XAM[I]I(6#PM(#W%:[?"[EZ3A:DFTJZZ>@EYOCS$P;$;
M_$;%Q0<U&MMJ5*INM&XODYV37#WGMY3\2[C++C+'6-R^@%GG1+A+BII\4.R#
M(;9[JG\&1RU7>&YUGO6VUSQ][T$[A_C?POQ'2SEVX7/\-RMM_P`:2?F;-]<.
MS0WMI)+930WL3I6ELMI+'=1N!C!!;)`Z1A!&G05674U*C33.QQ+EN[#?M2C*
M#V---=:,ICQEX_28Q&*5K(X-]45=V+62R^CPS?Z6<GFC9_.<?@0$E!9V]N=Z
M)AWB-TO<XN=3E&P5/,@+E`$!4:CT?"$`.L])]]`40!`$`0!`$!H_S4\]^'/*
MN_M</?8G+9K,7F/;DHK:R-O:VD=M)++!";B^N7.+722P/^*R.0@"II4*?B\/
MN94?B*2C;3IK[#D_$/B_!\/7HXMVU<NY4H;R4:))-M*LGTI[$SESB#[W?'=_
MOQ\/83`<.1&H;-,R;.7P'(=^Z-O9M=3^P(5I;X3CPUN.4GU+LU[3@,S^Y'&+
MVF%:LV(\[K<EVT7\)HWB'S2\Q.*M]N=XRSUY!(276<=[)8V%#^"+&P]EM=T;
M"TJ=:QL>S\N$4_)KULY+-X_QKB-5F95Z4']'>W8_Y8T788"6M))(!+M+B14N
M.TDZ25OJRGHGM)[$<6<4<->)+P]Q%FL*\1R:,;DKNUC/Q':'P1RB"0<SFE82
MM6KM%<C&7E1+Q^(9^"G+"O7;3I]&32ZJT?G1KG!_>/\`,G%&-E_<8OB*W8:.
M;E+!D5T\5T_MN.=:2%U.5S7J;=X;C2?N)Q?0_:0,;QEQG&>[=<+T%_B6O7&G
MK-U\*_>;PF8OK#&9SAR_Q%S?W=M91W5A<Q9*Q;/=2L@B=(R1MK>1QF5X!(;(
M0#50;O#)P3E;DI)+8]'[#I\#QQBY-V%C*LSMW)R44XM256Z+D3IUG4%#4BFD
M$@TTT(T'5SJK.X*$$:Q3I0!`$`0'E)#%**21L?\`.:#VZT!82XBTDTM#XC^(
M:CG^*_>'O("/EPD@TQ3,=HU/!:3[HW@@(^3'WD5=Z!Y`Y64>.GXM4!9T-:4-
M=G*@"`(`@"`(`@"`("YBL[J;2R"0CTMVC=)IK<0*("0CPMP[]9)'&-@J]W91
MO:@.M?*_#6K>#<89'22N\6^K4AC/WR8:`WXW)M51EO[=^8[W@/Y9#RR^M(V;
M%;6\/ZJ&-A](-!=_*=5U5&+@]D`0!`$`0!`$`0!`$`0!`$`0!`$!XS01SM`?
M44TM+30BM*ZP00:("P?CG#]7('#8\;IZP7`H"U?:7#-<9(VM^,.RI0%N01H(
M(.PZ$!1`6+_EN^<[WR@/E`$/5M-2Y`$WU[33^UW.KZYZGP[J\AS%[\3/]Y^D
M@;O+XNPWO:\A:PENMAF:Z7H$49?(3[BVQA.7=39$NYF+9^;<BGS5UZEJ8Q=\
M?8>&HM8KN]<-3FL%O$3\^8^)3\A;HXUQ]ZB*V[QW%A\M2F^I=;]AA^6XVR&3
MMY;.*""SMYVEDVZ73321DBK#(_=:P.`H:-KSK?#&C%J3=6BHR^,7\FV[48QA
M;EH^5M<U=G888I)4!`$`0!`$`0!`$`0!`$`0!`$`0&IO.;^$8/\`K=C_`(%X
MIO#_`)[_`'7ZCF/%OY7'^<OJR.72`=!%1L*N3YL?J5]P?1Y?\>@:AQG:4'(/
M_8;;5L7(>(OQ-O\`<];/T'_9W3@N8EL^]1^HCNM<\?7@@"`(`@*C4>CX0@!U
MGI/OH"B`(`@"`(`@/SE^]W_^DX?_`,/Q_P#W/++I>$?@W_,?H1\1_N3^>V__
M`%H_6F<KJR/GP0'M!;W%T_P[6":YD]"WBDF?_)C:XH]%5Z(RA;G==+<7)]";
M]!E5KP!Q1?1NK8"R8^-]'W\K+>E6.`)B'B3^HM3R+,7MKY"SM<#XG?BVK>Y&
MFV3IV:OL-;8SR%`W79OB$[76^*M=&O2/:KP]HB4N7$JZPAU_J(5CP>G[V7>\
MT%ZY>PVKPKY6<$8C+8F6/$F^N(LE82,GREQ+>.;(RZB<U[8JQVS2'`$?$T%0
MKV9D3MR6]14>S0Z'AWAWA.-DVY1M[UQ7(ZR;?*N39V'>VY&PD,C8P5.AK&M&
MOF`5"VZUY3ZXHQCI%)(H^..0%KXV/!T$/8UPZG`I5K5"4(25))->0C9L-CIJ
MGP/"=M@<8].W=TL[%FKLURU(L\#&G]'=?0Z$5-PUK-O==#9F?SX_HK8K_.B)
M/A;_`-J?6O6B*FPN1AJ?`\5HY8'-DT?-^*_L6Q7(/E(D\+)A]&JZ-?U]A&O8
M^,[LC'QNV/:YAZG`%9II["*TXNDDT^G0^4/`@"`\WQ12BDD;'_.:">LBJ`CY
M<19R5+6OA)_JW:!^2\."`CY<)*-,,S7\SP6'K!>$!'RX^\B^5`XC:RD@]2J`
MMO#D_JWCI8X?!SH#VCLKJ7Y$$AYRW<;_`"G[H0$C%A9W4,LC(QL;5[@.7D#>
MU`7\6&M6?K#)*><[C>ING7SH"0CM;>']7#&T[0T%W\HU<@/=`$!U)Y9_P;C/
MKK__`%LZJ,OY[.\X!^60\LOK,SU1BY"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@
M"`^7,8_Y;6N^<`??0%NZQMY#0-,9/*PZ-7HFH0&/S6A$D@:\&CWCXPIJ<1R5
M0'F+5YUN:.BI/P!`>S+6,$;Q<[2.8=FE`</<997)R\2<06S[^Z-O#F<G#%`)
MG,B9%'>3,8S<86M(:T4TU*Z*Q:MJU%I*KBCY'Q7*R9Y]^W*<MR-V:2K144GS
M&'<M>4ZSRGW5OV;"J"]`0!`$`0!`$`0!`$`0!`$`0!`$`0!`:F\YOX1@_P"M
MV/\`@7BF\/\`GO\`=?J.8\6_E<?YR^K(Y=5R?-C]2ON$?P!Q[_YG:?\`8;;O
M7(>(OQ%O]S_4S]"?V=_)LS_VH_41W6N>/KH0!`$`0%1J/1\(0`ZSTGWT!1`$
M`0!`$!0D#22`.<T]]`:+\UO)+A/S1O;?+Y#+9?$9NSQ[<;!=8[V>ZM9+:*::
M>)MS8W+-U[F2SN^,R6,D&AK0*=BY]W%B[<4I6VZZ^TY/Q#X1P?$-Z.5>N7+6
M5&&ZG&C5$VU6+Z6]4T<YW'W2\G;RO?!Q3;92V!K'"RT.+O'-]%[KB6\MFOZ'
M45BN,6WHX-/RU1QD_P"V>1;;<<F-R',H[CZVVBR?Y,,X<&]>\*7MQNZ3=78D
MR4)W?PJV[GVK1HY6A9K-^+W9K7S&/_REK!UNXTY4Y95DNSW>PN(88+5HBMX8
M;9HT>'#''`!310L8UE*<X7C;>W4D0A9MK=MQC%+D2IV$K9X;+9.K<=C+Z\):
M[3;VTKV:CKEW1$T=)"URN0CWFD2;5B_?JK$)STY$WV[#'[+RUXCNJ.N1:8UA
M_P")G$LH%=/Z*V$NGF+@MCR;<5I5D:UP3-N4W]V"Z75]2J9KB?++'V4\%U>Y
M&YO98)8YF1PQLM;??B<'LWB3-,]H<W55M5IGDRDG%)),M,?@=FU-7+DY2E%I
MZ*BTZV;-)J:[5&+T(>!`$`0'R]C)!NR,9(W8]K7CJ<"FS8>2C&:I-)KIU(V;
M#8Z:OZ#PB>6%SF>K5S.Q9JY-<I%G@XT_H[KZ-"*FX;Y;>Z_)F9_/C/\`-6Q7
M^=$2?"WMMSZU["+FPN1AJ?`\5HY87"31\W0_L6Q78/E(D\'*A]&JZ'7]9&/8
M^-V[(Q\;O1>US#U.`*S33V$5IQ=))I])\H>!`$`0!`$`0!`$`0'4GEG_``;C
M/KK_`/ULZJ,OY[.\X!^60\LOK,SU1BY"`(`@"`(`@"`(`@"`(`@"`(`@"`(`
M@"`(#Z9\H>[[Q0$#-^ME^L?^<4!YH`@-7<7>4_#_`!3=2Y*.:?#92?XT]S:,
M9+;W4E*>+<VDCF`S&FE[',+N6I4RQF7+*W>]!?IM.>XEX<PN(7'?BW:R'M:U
M3?.T^7I372:?RGD9Q3:;[L9>8S+QMTM9XK["Y<-GAW(=`7?WJG0XC9EWTXOK
M1S.1X1XC;UL2MW5Y=U]3T[36^4X2XGPN]]J8+)VC&D@S.M7RV^CE%S;^+`1^
M4I4+]JXO=DNLH\CAN?B?B+-R*YZ576JKM,=!!K0@TT&G(=A6X@E4`0!`$`0!
M`$`0!`$`0!`5:USW!C&N>\ZF,:7N/0UH)*\;2U>P]2<G2*;?09%9<)<17]##
MBYXXW:I;K=M(^G].6/(Z&E:99%F&V2KT:D^SPO/O:QMM+GE[OIU,LM/+&^>V
MM[D[6W=_5V\4ET1TO<;=O551Y9T5W8MEE;\.WVOMKD8OH3EVZ%;GROR/_P`=
MD+>[?R13036[R=@='[0WKHD<Z+[T6D>S\.9'^Q<4WS-->BIK[C7R!\R^-\5!
MA<5C,?:3-REK=27>8RUK8V++>.*Y8^0/:9[B4AT@^*V(N.Q3,;B>)CS=R;;6
MZ]$JLH.->"_$'%L6.)CVX1DKBEO3FHQI22Z6]NQ*I?<)_<(?OP7''/F!&8P6
MNGQG"6-<YSVZW1#,99S0RNK>;:&G(O;WB-4ICV]>>3]2]IJX=_9V58SXOF^[
MRQLQU\F_/9Y=P[PX)X&X7\N^'K3A?A#%Q8K$6A=)N!SIKF[NI`WQ[[(7<I,U
MY>SEHWGN.H``!H`'.Y&1>RKKO7G6;ZO,N1'V#A7".'\$PH\/X9;5O&CK3:VW
MME)O64GRM^:BT,M6DL@@"`(`@*C4>CX0@!UGI/OH"B`(#SDE9$/CG2=(`TFE
M:5IR:4!9NOO09[KC\`0%NZZF=^%N\S13MTGM0'BYSG&KB7':34H#Y0!`5!(U
M$CH0%A+C,9/()I\;CYI@:^++96TDE=N^^(N/6LE.:T3=/*S3+'QYRWY6X.7.
MXIOT%X:-B<QH#6-C>&L:`UC1N'0&BC0%XN\GRFR5%!I;*&DE8+8<R]H7IX$`
M0!`$`0!`$`0!`?+V,D;NR,9(W3H>UKQIUZ'`HFUL/)1C-4DDUTD;-A<=-4^S
M^$X_A0N,?J_&9V+-79KE(L\'&G]&CZ-/U=A%3<-ZS;W70V9G9OQG^:MBO_XD
M1)\+_P#'/K7K7L(*\L+JQ($\=&N-&2,._&[F#@!1W,0"ML91ELVD"]CW;#^T
M6G.MA9K(T!`$`0%K=WUECXS+?WEI8Q@5W[RYAMFTV@S/8"LHQE+2*;?087+M
MJRMZ[*,8]+2](M+VRR$8EL+RTOHB*^)9W,-RRFTN@>\#W4<91TDFF+=VU=6]
M:E&4>AI^@NEB9G4GEG_!N-^NO_\`6SJHR_GL[W@/Y9#RR^LS/5&+@(`@"`(`
M@"`(`@"`(`@"`(`@"`(`@"`:]`TH".R68Q.&C=-E\IC\9&T5+K^\M[71M#9I
M&O=[@*RC"<W2";?0C1?R<;%CO9-R%M?M-+TFL\EYX\`V,AAL+O(<1W8J&V^!
MQT]T'.U!HN)Q;P:=K2Y3(\/R7K.D(\\G0H;WBS@]M[EB5R_<YK<6^UT754AK
MWS(R$D;)[;!/Q_M+&S-&4\5TT7C#?#'QL9!'OLK0C>.E8K&A765?(9SXW?=M
M3C9<-Y)^_6JKR-*FOG,4NN,.([HG>R<L#3^!:-CMF"NPQM\0^ZXK:K-I<G65
M]SB>;<VW&ET:>@M&<1YZ-V\W,9"OXUS(\'I:\N:0LOAVZ4W50UK-S([+L^LG
MK/S`SMO1MP+6^8*5\:'PI2.7]+`6"O2TK6\>V]FA,M<9RX*D]V:Z51]:]AE5
MGYC8V6C;ZRNK1QUOA<RZB!Z/T4H'N%:98TEW6F6%OC=B7S82B^C5>IF5V7$F
M$OJ-MLI;%SOZ&5_L\NGD,<XCJ>856F5JY':F6%K.Q+VD+D=>1Z=C+7*<'\+9
MMI=DL!B[IS]/M#;9D$YKRMNK3P92>?>*RA>O6^Y*2_3F9KR.&</RU6_9MR?/
M2CZU1]IK;*>1G#%UOOQ=_D\3(:EL;G1Y"V!/XDXCN`T?6J7#B-Y=])KJ*+(\
M(X%RKQYW+<N;22[:/M-<Y3R-XJM-Y^-N\9EXQ4AK9GV%R=@\*Y:82:;)5*AQ
M&S+2:<7UE'D>$N(VM;$K=V/EW7U/3M-;Y3A/B;"D_:F!REHP5_3.M9)+<TY1
M<0"6`C\I2X7[-SN23\Y19'#<_%_$6;D5STJNM57:8]4'45M(15`$`0!`$!-8
MKA[+YK>=C[-TL3';C[A[F0V['4!W3+(YH+J'4*E:KEZW:[[)F-@Y67K8A6*Y
M7HNMF;67EC>O`=D,E;V^V.TC?<O`V>)(88P:;`5%GG16D$WY2WL^';LM;]R,
M>B*J^MT1EUAY></P$;]O=9*31HN)7EM=6B&V$0ITU4:69>?*DBTL<"P8;8RN
M2Z7IU*AGN/X8=;-#;+&6]BP`4<(HK<TYR!XKO=4:=URUG*K+NSPYP5+-N,%Y
M$OUF01<.DZ;BZ'.V%A)Z-^0C\U:M_F1-C@?^2742<.&Q\5"83,1IK,\O%?FC
M=9V+QSDR3'$L1Y*OI))C&1C=C8R-OHL:&#J:`L"0HQBJ122/5FL]'PA#TN62
MR1_(D>SYKB.P&B`NV9*Y;\HMD^>VAZV[J`O&96,_K(G,YVD/'4=TCM0%_#<0
MSU\)X<1I(-0X#5J-"4![(`@"`J-1Z/A"`J0*G2-9V[>A`4H-H[>Y`*#:.WN0
M$/=#].^IV4KO:J#5HU("WH-H[>Y`*#:.WN0"@VCM[D`H-H[>Y`*#:.WN0"@V
MCM[D`H-H[>Y`*#:/=K3W:BE$!KG(VO#DLLC[7*>ROWCO1&VNYX-ZNGPW,AJU
MO07#9H4N$KJ6L:HI+MO#<JV[E'S4;7FT,=FACC=2.Z@N!R.C9<MZQ-;Q$=JW
M)UY&B)*,4]))KS^M(\*#TAZWT4,10>D/6^B@%!Z0];Z*`4'I#UOHH!0>D/6^
MB@%!Z0];Z*`4'I#UOHH!0>D/6^B@%!Z0];Z*`4'I#UOHH!0>D/6^B@%!Z0];
MZ*`B\T!]F7%7-_HMW>K\KQF:JMUTJL[?S%S$//I]TELK54\M?94P+='IMZG_
M`$5,.>&Z/3;U/^B@&Z/3;U/^BO0<_>9(\V'9:_'#[LBSAIL=O[,<,(#<O_9H
MS<F3V5K\KHN"\:0T4U:-*L,7[GN+XM/B]/Z4.4XO_7?CR^Z[_P!THJ;E*[%6
MM/>VU]1S/DF9'VIWVS+>>VU._P#:@OO::UTU]LC\76K:.[3W*;O13U''7E=W
M_P#D.7Q/VJU[=3UP\-])>1MQ%W/!=DC=DL&Y0S`UV8RUFN#U+RXXJ/OJJZ:>
ML]L1NNY2PVI_L[U?X54[&\H,3Q2W-XYW'G%.3?PH8[DWL5SC+L78(MY#:MCG
MOK(9<!UR&@EL3M!.H:51YT[7PG]WA'X_)JJ=CH?0/#UG.^]P_JMZ?]/H]ZL7
M79IK);^VFQ>4_1K"C%?9-C]B.@^R?`;[%X&_N&*IJ3OM$GB%]=_?^/O5WM*Y
MFYO[[^)WZZGVC$^[_=X?=*?=Z>[3]*[=M=:DI0;1V]RUD@4&T=O<@%!M';W(
M!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@%
M!M';W(!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@(_(7EQ9Q%]MBK_+24
MJV&QEQD))V.DR>0L&-KM%5E&*DZ2DHKIKZDS1?NW+4:V[4[DN:+@OK2B:PS'
M$WF[)O1\/^6ME:@U#;G,<286[EZ?9K3)VL+3S&1RF6[6$M;MUOR1?L*')S_$
MDM,/!C'IG=MOL4TNTTOQ:[[Q,T,DF4CS%K9FI=!PS["8VMV..`DNKS=`])Y4
M^S_2T_<W6_VJ_P"HY7B+\;2BW?5V-OFM;M/_`,VWVF#<(MX0#[IW'4A=GS>$
M1,SHRM1`(F4,OM$8BWS-O5\0UYJ+;D_>*)8ORJ?1I_U(/!UP>DGQM_\`.WW1
M7-_91;:Z;:[3?6*&(\%OV(<9X&B@Q?LVY3\;V4>^JBY\3>^UWM[IJ=YB_<MW
M_A?"W*?0W=G_`&F4-W3`SQMP,W`"):%E`-9WANZ1M6*Z-I.=-WWZ4Z3%,J.&
M3#.-ZS;=>%)X1M?$KXNZ=P.]G:Z/2[TM"VP^)R5H5>5_3]UTW?BTTIS^;0P*
M@](>MW+>4XH/2'K?10\%!Z0];Z*`H0VFES:<]:?FKT:&08@<2;S?L9V3I44]
MF]H]GU\M6^STKMT+5/X7T]VOFJ3,99M5]U^)YJT]AL2SNO,.`-]IQMI?,T?K
MY[&":G.^"ZCH>EA4=K&>QM=9=VKG&H?,MQG'I<4^Q^HRJSR&3EHV]P-S:.Y7
MQ7V.NHJ_^IAD`]PK2XP7=DGYF3[5[(EI=LRCY)1:]*9-"NZ=-!3XP-:`<N]0
M%M-O(L"5R=!K3BK_`.JOC_[F_P!LF<D[YBW/M$'EK]E#V[>Z05*L_>Z?9;^[
MV=I0<0_^<U^__`WJ<G>_@]XTME,+Y+W6^[%\89/$R&NZQ^+S&0M@>0;D^+BN
M-W^]*L(7,]=ZW&7G2]9RV1B^%KE7C9-RV_W)R7;!/M-<93$8BS)=C>*\7F(]
M-`S'9^PN.8&.ZQ7@5/UJEPG<EWX./G3]91Y&-C6G]AD6[L?W;D7U.%.T@-T>
MFWJ?]!;2&-T>FWJ?]!`>T$$<T@8^\MK5IUS7#;QT;>D6MI=2GW&E8R=%L;ZO
M6T90BI2HY1CTNOJ3?8=(\`X[#V^`A9_N"WOH_:KI[I;&QR<48>YS2^$&_L[>
M4^'J+O#`/(J;+E-WFW%I]+7J9W_`[&)#!2^,IQWY:QC)+;L]Y)]AL.W9PZQS
M1XK9'Z/C7(G#:]#XHXE%^TJ7UM8">C3?37UF10B#<'LY@W/[#=W?=\,46MUY
M2?#<I]G2G0>M!M';W+PR%!M';W(!0;1V]R`4&T=O<@/M@%?E#5^-S<R`]:#:
M.WN0"@VCM[D`H-H[>Y`2>,`\<Z1^J=M],<R`G:#:.WN0"@VCM[D`H-H[>Y`5
+`%#I&KGVCF0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g28048tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28048tx_pg03a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C0+&`P$1``(1`0,1`?_$`.```0`!!`,!`0``````
M```````%`08'"`(#!`D*`0$``04!`0$!````````````!0$"`P0&!P@)"A``
M`0,#`@,"!@@/#00(!P$``0(#!``%!A$'(3$2$PA!46%Q(A2!D;$R4Y34%?#!
MT4)2LB,S<[-4E=4V":%B<B0T=+0U5746=M9#9+66X6.3TT0E%S?Q@I*BPF56
M&1$``@$#`00%!P@(!`4#!0````$"$0,$!2$Q41)!87$3!H&1T2(R(P>AL<%2
M<K(S%$*2TG,T%34(\.%B=(+"4],6DR08HD.S)1?_V@`,`P$``A$#$0`_`/W%
M$G4\3S/A/CH"FI\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\
M9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@/+.
M),*5J3]Y5[HH"R*=72"Q<DW!L>/A<=M8NER&J?5(KB>S94"/Y5)!4AK16FJ4
M]2_(*V+6-<N;7ZL>+(C.UG$PV[<7WE_@MWE9@'(<QO>2.'UZ1V<1*^IFWQ]6
MHK1'O2I(]-]P?9+)/BTJ3M68652&\Y#-U'*SI/OG2W]5;E]+\K+8ZC]!5]6L
MIH#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U
M:`E+5?+I99(EVV8[&>X!72=6W4@Z]#S1!;=1KX"#Y-*LN6XW(\LMQL8^5D8E
MSO<>3C/_`!T;C.F.;IVZ?V<6^-IMDHZ($M!)@.JY`KZM5Q"H_9%2>/,5'7,.
M4=MO;$ZO"\06+S[O,7=W/K?HM_1\IE5"T.(2XVM#K:TA2'&U!;:TGDI"TDI4
MDCPBM-IIT>\Z%.+7-%IQ?2MS.5"HH!0"@%`*`4`H!0%UV0GU-?X97N-_5H"6
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT!Q4X$#J6OI3XR3[0',D^*@(MZXJ/HLZ
MI!YJ(]/SIUY:^7C0$<5*))*E$DDDDDDZG7B:`IJ?&?;-`-3XS[9H!J?&?;-`
M-3XS[9H!J?&?;-"JWFG>4_K+D!/]L7#^DN?4J<M?A1^RCS'4')ZC>BG3WDOO
M$#P\OM_]%9#4Y9_6^0QYE^V..YAUOK:7;;ROWET@)`==5]:F9'X-S$C3GZ+F
MG)0K;Q\R[CO8^:WP?T,@-6\-8&JMSDN[S7NG'>_M+=)?+UF'QW?,HM\LN9%*
M:BV3K"6)L'K7(F!0)2GL70/F]9_ZW4Z^]!YUOO5;4XTM)NYP9R*\":CCW7+-
MDHX==DHU<I+K7Z/E,L63'K1CL7U2TPVXR5=)>>)+DF2M(.BY#ZR5N*U/+@D>
M`"M*Y<N79<TW4ZG#P,73[7=8L%&/2^E]KZ2:JPVQ0"@%`*`4`H!0%G9-@MAR
MA)<E,JB7#IT1<X>B).H'HA]/WN4@<M%#73D16:UD7;.Q;8<")U/1L+4TYW8\
MN1T3CL?EXKJ\QKKD^W^18R5OK;-QM@)*;C#0M24)_P![8U+D8^4ZH_?5+V<J
MU>V5I<X,X#4]"SM.DYR7>8]?;CM_66]=NXL3M%>`ZCP'CQ_=K9(0IVJ_'[OU
M:`=JOQ^[]6@':K\?N_5H"?QO&LDS"Y-VC&K3-O$]9&K41I2D,))T[67(44QX
MC">96XI(TK%>OVL>'/>DHKK-_3],U#5<A8FG69WK[Z(K8EQDW2,5UMHW@VX[
MJ=KMACW7<68F^3D]+B<=@NN(LT=0T(1/E>@_<BGPH2&VM>'I"N<R];G-.WBK
MEC]9[_)P/9O#WPOQ\?ER=?FKMU;>ZC^&OM2WS[$DNMFW4.)%@16(4*.Q$B16
MD,QHT9I####*!HAIIIL)0A"1R`%0,FY2<I-N3WM[V>JV\>U9MQM68QA:BJ))
M)))<$BZK.?N#_P"&3]H:P7/:\AO8RI%]I--NN-+"VUJ0H>%)TU'B/@(-6&R3
ML:[A6B9&J%<!VB2>@^521[TZ^Q0$N%]0!2OJ2>(4E6H.OB-`5U/C/MF@&I\9
M]LT!4$Z'B>7C/C%`4/,^<^[0%*`4`H!0"@%`*`4`H!0"@%`*`4!:66Y79,;M
MTLW&4/62PKLH#'2[,>/`C1K4=F@_9+*4UEMV+MSV5ZO'H-',U'$PHUNR]>FR
M*VM^@U0R;<>]7P+C13\TVY1*2Q&=5ZR\C7@),E)2O0CFE'2GSU(VL6%O;+;(
MY#-UO*RTX0K;LOH3VM=;^@QV3KS^CQD^$DUM$0W4I0H*`4`H!0"@%`*`4`H!
M0%U8]F-[QQQ(@R.TB$_=($DJ<B+'(E*=0IA>GUR"D^/6L%W'MW526PW\/4<K
M!E6S+W;WQ>U?Y>0SYCFX-DR#LXZUBV7)6B?5)3B>S>5IRB2?1;=.OUIZ5Z>`
MU'7<:=O=MCU(Z_!UK%S/4F^2]P>Y]C+[K7)<4`H!0"@%`*`4!=5D_D;GX9?V
MK5`2U`*`4`H!0"@%`*`4`H!0"@(VY'T61^^43Q/$@#0^P#0$30"@%`*`4`H!
M0JMYI[E/ZRY!_?$_^DNU.6?PH_91YCG_`-2O/HYY?>.NW6*;<-%A/81R?OSO
M#J'_`%:."ED^`\!Y:3NQCNVC'Q;]_P!:G+;X^A%]V^S0;:$J;0'7]"%2'=%.
MZ^'IT'2V#Y/;K7E.4MY,8^):L[4JRXO>=61MH=L5U2XD*"8;SH!&NBVD]HA0
M\1"A5;5>\36],IJ$8RPKO,JTMM^;::^U*G""@%`*`4`H!0"@%`*`<]00""""
M"`001H00=00:#?L,793M99+[VDJV]-DN*B5=3#85`D.'77MXB=.R)/US>GE!
MK;LYMVUZLO6A\OG.:U+PUA9C[W'2LY#K[*]5OKCT=J->,@Q2^8P]V5VAK;;4
MHAF8UJ["D#70%J0D=/41]:KI6/"*E;5^U>5;;J^&YG!9VFYNG3Y,J%(O=);8
MOR\>HMRLQI--;RA.@)\0)H49]=]F[%:;%MKA[=J@QX9N./VNY7!UEI"7ITZ;
M%:DR)4MX)#C[BG'3IU'1*=`-`*X//N3NYEQW&W2;2X))M?0?57A+!Q,/P[B1
MQH1@[EB$YM+;*4HIN4GO;=>G<E1&3JU#IA0%Q6;[P]^%3]I6&Y[7D-JQ[+[2
M7JPSB@)6TN+$@MA1Z%-J)3KP)!!!T\!H"XZ`4!4<CYOIB@!YGSGW:`I0"@%`
M*`4`H!0"@%`*`4`H"/N=VMMEC*EW28S#8`5TEQ8ZW5`>\8:&KCR_(D&KX0G<
M=(*IAOY%C&CSY$E&/ROL728-R7=>;,[2)CS2K?&/4DW!X(5.<2=1JRC13<4>
M(GJ7YC4A:PXQ]:XZOJW'*9WB"Y=3MX:Y(/8V_:\G`PU<GG7V);S[KCSSB5*<
M==67'%J)!*EK62I1]FMU))4CL1SC<I2<Y-N3WMNOSEC'F?.?=H4*4`H!0"@%
M`*`4`H!0"@%`*`4!77EY#J/&#IIJ#SIOW@R'C6X]ZL0;C2E&ZVX$)]7D.$2&
M$#0?Q:20I8``X)7U)\U:UW%MW-L?5D3&#K65ATA<K=LKH;VI?Z7Z>PSW8<JL
MF2-`VZ2/60D%V"^4M2VO&>R*CVJ/WR"4U&W+%RU[:V'7X>H8V:JV9>M]5[&B
MXO\`X?1XZQ;]IO"@%`*`4`H"ZK)_(W/PR_M6J`EJ`4`H!0"@%`*`4`H!0"@%
M`1ERY,^=?N)H"*H!0"@%`*`4!Q4M*.9]CPT!@"=8X2+[=ISJ?67G[G+>2ET`
MM-=;ZE)"6^*5*3XSKQ\`J2C<;MQCT4./N8EK\Y=N2VR<Y/;T5?\`C:>LG7P`
M:<.`TH9DDMQ2A4B;_P#U'=O[OE?BC5]KVUY/G-//_@KW[I_,S7JI4X,4`H!0
M"@%`*`4`H!0"@%`=3[#$IAR-*8:DQG04NL2&TNLN)(T(6VL%)%$VG5-U+;EN
M%V#MW8J5M[TTFC"N4;/19!<EXP\F&Z=5FU25J,1:N93%DGK7&//1*^I/E`J0
ML9\HKEOJJXK><=J/A*U.MW3&H3=?4E7E\DN@P%=+5<;/)<A72&_!DI!^YOH*
M>M/'1;2_>/-GP*22#4G"<+BYH.J.(R<>_B7'8R8N%U=#^CBNM'U^VS_]N<#_
M`,HV#_AL>N$R_P"+O?O)?>9]7>&_Z#A?[2U]R)>]:Q."@+BLWWA[\*G[2L-S
MVO(;5CV7VDO5AG%`25J_E8_!K^E0%S4`H"HY'S?3%`#S/G/NT!2@%`*`4`H!
M0"@%`*`4`H#%N;[B#'WU6FTMM2;HE/\`&GW=5L0"M(4ELM@CMI720="0E.O'
M4\*W,;%5U<]QT@]W^9`:IK?Y27Y?%2E?6]O<J_.S7VX7.X7:0J7<Y;TV0O75
M;RRH)!.O2TC@VT@>!*0`*DXQC!4BJ(XZ]>NY%QW+TG*?6>*JF(\L[^22"?`V
M?I4!91YGSF@*4`H!0"@%`*`4`H!0"@%`*`4`H!0':T^\PXAUAUQEULA3;K2U
M-N-J')2%H(4DCR&C2:H]Q=&3C)2BVI+<UO,R8ENA*0['MV1J$AA92TBZA.DA
MA1(2A4P)T0\SJ>*P`I(XG6M"_BK;.WLZCI=.U^XI1L9OK1>SFZ5PKQ7%[S/'
M`\4D%)XI(.H(/$$'P@BH[MWG7=FX4`H!0"@+JLG\D<_#*^U;/N"@):@%`*`4
M`H!0"@%`*`4`H!0$9<N3/G7[B:`BJ`4`H!0%"0.)X4!T+?YA'#P:\?<-`=!)
M)U)U/EH#$MS_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.[?W?
M*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`C+O9[
M7?8BX5VA,36%@Z!Y/IM*(TZV'4Z.L.`<BD@U="4K<N:VVF:V7AXV;:=G)A&<
M*;*]'6GO3-P\1M+=NQ#%H40N&/$Q^U1V0XKK=#;,-EMOJ5H.L]*>)X&H&_)R
MOSE+VG)M_.>LZ5CQQM*QK-GV86(17&BBOH)KEP/,5B)"O04H"XK-]X>_"I^T
MK#<]KR&U8]E]I+U89Q0$E:OY6/P:_I4!<U`*`J.1\WTQ0`\SYS[M`4H!0"@%
M`*`4`H!0"@%`<5J*$.+'$H;<6`>1*$%0U]JJK>6R;46UO29I-)D.RY,B6^HK
M?DO.ONK))*ENK*U$D\3Q5PUJ>244HQW(\OG)W)RN2VRDVWY6=-5+!0'4\@.-
M.-JY+0I/M@Z>?C0%D.M*9<6VL:*2H@CW#R`T(-`==`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!2E=X-L<!FO3\1M#SZBMQMMV(5DDJ4F(^XPV5$\SV:0/8J'R8J-
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MM'-'LH!0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!Y7EDJZ>`"0!P\
M/(ZGRT!TT`H#$US_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.
M[?W?*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`4
M#-Q<7=;>QG'UM+2XCYIA-]22".MMA"'$ZCZY"TD$>`U!7?QI]IZWI4HST^S*
M+3CW<?D23^5'OEH`*71PZE=*@.7`:Z^SI6,V+RI1QV'DH6%Q6;[P]^%3]I6&
MY[7D-JQ[+[27JPSB@).T@F5KIP#:M3QX:Z`>V10%RT`H"HY'S?3%`#S/G/NT
M!2@%`*`4`H!0"@%`*`4!UO?>7_P#WXI=56]=I;/V)?9?S&D53YY8*`4`H#QR
MH3$H?=!HO0A+@X+3QU`Y:*2/$:`MR5;GX^I">T;UXN('+^$D:E/[HH"/*2GG
MIQH"E`*`4`H!0"@%`*`4`H!0"@%`*`4!M-MI^IMM_#S_`.F/5$YGX\O)\QW^
MA_TNWVR^\R^ZU26/CI^VT[I5Y[RW=*<S;#!=)N?=VV?=]SK7C<%<EYC*<1EV
M]B#N#;T6QHJ1*OEKL<)%QA+2@N],1]E/!\UR_BS399VG=_:J[UA\R2Z8O9+9
MQIM73P/J+^T[XD8O@;XC/1M4[N&DZ["&+*[)*MJ\I.6.^?HA.;=J:;I6<)/V
M#\.T-F1<)$.';HLFX3KA(C0[?!A1W)$N?,F/(8A0X;"$J7(DS'W4H;0D$K6H
M`<Z\GKS>K%-M[$N)^LMQPLPE=O24+4(N4I2=%%159-M[DDFV^A(_5WC7>%RC
M]D)L=LAW4L(L>)Y[OC-Q^7O'WCDYI-O=QL^`9IN2B%<;1M]C\*TW2`W`FV2R
ML-B8->A:@E[IZI"E5]5_#7X<PRM![[4YWK<7+9RM*LOTMZ?JK9'9ODFS^9W^
M_?\`O8R+7QNO8_@;$P<NW:M1MRE>4Z1L0JL:O=SBW=O+GR)<S?):G9A2ANKW
M"?VL64]Y+>]K9G>G%L!PQ[++/).W=VQ/YYBHG99;B9;V.707JZ7%+CMWM:7%
M0BWT$OL]F>HN)TZ#Q3X$L:-ISU'3KEVY&$UWBG1M0>Q27*EN>_8]AX1\#?[I
M=3^(GC1>$/&&+@X=S*LO\K.QWB4K\?6=F:N3E5W(*7=TH^>/+MYE3[BD:5YH
MMJ/M);54I0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!XG/?J\]`<*`
M4!B:Y_UC/_GDC\8JM^'LKL.:O_Q,^U_.>&KS&*`B;_\`U'=O[OE?BC5]KVUY
M/G-//_@KW[I_,S7JI4X,4`H!0"@%`*`4`H!0"@%`*`4`H"XL?RJ]XT]UVZ42
MPI?6[!?U=AO:\^MDD="R/KD%*O+6&[8MW5M6TD,'4\S3I<V/+U'OB]L7Y./6
MJ-&;+=NIC,]F+'N\EC'[A*D,QF6[@^VW#E2G$N%#,28YT-]HYV9Z4+Z5$C0:
MU'3P[T&^1.44JNG0CL<;Q-I^1&,<J<;-Z3HE)TC)NM%%OI=.DOOR^`\0?&"`
M01Y"#6L3R:>U5+BLWWA[\*G[2L%SVO(;=CV7VDP`5'1())Y``DGS`:FK#.2\
M:TN*/7)/9H^#&A<//F>2/W30$XTRTRGH:0$)YD#PG3F22230'90"@*CD?-],
M4`/,^<^[0%*`4`H!0"@%`*`4!$WN_67&K<]=K_=(5GMK`)<ESWT,-Z@:]FT%
M'M'WE`<$-A2SX!5]NW.[+DMIN74:V7F8F!8>3FW(6K"WN3IYN+ZEM-4+[WP;
M'$O'JU@Q29>;*V[T/W.7.%LER4]72MR!;_5Y&C9'%/;*0H^$)J5AHUR4:SGR
MSX+Z6>=9?Q+Q+63R8>-*[BI[92ERM_9C1^2K5>E(V`PK=##-QK:Z_C5U;<F)
MBO+E66641KS"^Y*ZNVA*62ZTD_[1HN-GQUH7L6]C2]XO5KOZ&=EI7B#2]<QW
M/!N+O>5UMRI&<=G3%[^U5J:QU+HX84`H!0"@%`14NULO]2T?<G#J24^\/+WR
M.7'3F.-`6[(AOQ3HZ@Z:Z!8!*%>+17+CXCH:`\U`*`4`H!0"@%`*`4`H!0"@
M%`*`VFVT_4VV_AY_],>J)S/QY>3YCO\`0_Z7;[9?>9D%EAZ0L-LMJ6K4`@#@
MG7PJ)X)'#PUJDL8H[R&\.,=V/8W/]ZLQ+4UK%+0L66QEU+/^(\LNBO4,9QME
M1T+J[I='D!W3@F.EU?%*#4IHNEW=:U.UIMG?<EM?1&*VRD^Q;N+:1Q'Q'\<Z
M?\-_!>=XPU%UCBV_=PK1W;\_5LVH[:UE-JK6U14I=!^8%G]KSWN8[K4ABU=W
MUAUEU$AE+.QV+-!I;3@<0AE]"DR&PV4@)6E0<&FH/57LW_\`-?"RI2%ZJ6]3
M2=>-%$_.-_WJ?'R5>?/PW&6].Q)II[T_>[5T/J-;.^`%97N'$[QL.XS+EB/>
M=B2]S+9,N<U4V9C^8-OMVK<G;2XS'"-9>`9.RIB(@Z*59'H#@&BQ70>'VK&+
M_)Y14;^$U;:2HI0=96YI<)1]KH4U)=!X]\5ZZGK\?B!9G.[I?B.,LN$I2YG:
MOI\F7B2EL];%O)Q@J+_V\K$J)2+;[K&,L7K=.'GETO-PQ[`]BXJ-Z=P\GLLO
MU2ZVVQX5<(<JUV:PSDDI8RO-\G5#LUK',R9G7H4MJK-KE_N\)XD8J>3DONH1
M>U-R3JY+ZL(\TY/@C1^&>FPR_$L->RKUS'T/1(_S#*OVW2<+>/*,H6[4ENO9
M%[DL6>GGN<U*19N]</VU'?;F3Y\J#.VKM<27,ER(5L.W4*;\VQ7WW'(L`S7I
MX>F&"RM+9=6`ISHZCQ-<U'X;^'(P49+(<TEM[QJKXTIL3WTKLJ>SY']XWQEN
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MU9_AW=,VZVM:P=6_V_VQ%EWOW!SO++3,EX)M/@4:T8^UD.9'#;//@2[_`'O(
MLMOR+?8K3ZY&C%Q+KCSO9,E*JI*C;Z`=.Z&8]Z;NA6F'O-N)NWC/>1V)M-_Q
M^#O197MJ;-M?N'M[B^17F#87=Q<$NN+7FX6B^VG$YMQ:>N%KN+';*AE:VY'4
M@U1)-T0,S=TW>',]S(6\N";H2[1/W:V&WPS#;+*)ECMK=FMU^QF4XSE.U.70
MK4TMUN.QD^W]YB+*D$H<?:<4/"`=.@&M1[Y6[M^RG=:W[9V/$\L>S3O.O=U+
MNGV.\L/0,?7<]KL2=N^_^].X%_MJU7>[X1B%Q8EA,2+T+<5"3';6E;Y6E0&1
M=QK9WZ=EL/ON[]IWOP'O$JPFU2\JS'8R?LE;-M8F48Y9HR[ADEMVPS*P9+>+
M]9,FCVN.\[;479-P9E.MI:=*2O6J['L0.^X]Y#<3?S-<&VR[I5QQ#'8M]V5P
MC?\`W$WHW`QZ;E\+`<)W-[8;=8CCN#PKI98^0;C92S#E25^N36H-OAQ2M:75
M.(35O:#,>+8[W@=MK'N1?MR=^[%O';;=@=_NV+QCLW8MNKO9<DM%KN%R3*FW
M#'\BN,"]69UN,E'JRXK3B5:DNJ'"J^KU@Q3W8X_>NW5VJV'WMS'O'X\]:MP<
M(P/<3)<$MW=UQ>VL+AY%:X-WN.-0<K1ECD^&WTR2RW-#"G$C1?03PJLJ)@QA
MM)WMMVGN^#N3M1NPK&'=E,JWDW2V3V&OUILR+5<\8W*VGL^/98]@F97-+RV[
MO,S_``^_O2[2XL-N+>MCK:0KJX5<53KH#93!-T,LRKO%=Z';*\/6]S%=HU[)
M##6H\!N/<&1GVWKF29#\Y3TK*[CVET0"SU!/8M^B->=6TV5!GVJ`4`H!0'B<
M]^KST!PH!0&)KG_6,_\`GDC\8JM^'LKL.:O_`,3/M?SGAJ\QB@(F_P#]1W;^
M[Y7XHU?:]M>3YS4S_P""O?NG\S->JE3@A0"@%`*`4`H!0"@%`*`4`H!0"@%`
M8FWF`.'L@\1\^0/Q$VMW3_QW]E_0<QXM2>EQK_UE]V1:VVW>$S?;[L+>^\K)
ML;1TH-GNS[BGHC0X$6JY'M)$0`<FU=HUJ/>CG6;,TK'RO6CZEWBNGM1&>'O'
MFM:%3'NR_,Z<MUN;=8K_`$2WQ['5=1]-MDMP+#NW8KE>,>1/B-6VX1X5SC7)
MA+;T:8]$$D,LK;<=9EH#:O?I(3KX->%<AGX=W"NJ%VFU;*=)]!^%O$6#XCPY
MY."KB[N:C-323C)QYJ53:?:C/L>(S&'W-/I>%P\5GV?`*T3J#TZT`H!0"@*C
MD?-],4`/,^<^[0%*`4`H!0"@%`=;SS,9EV3)>:CQV$%U^1(=;889:3Q4X\\Z
MI+;:$CPJ(%$FVHK:V4E*,(N=QJ,$JMO8DNMFJFX_>GQW'R_:\#99RF[)"FU7
M9U2V\>AN:%)[(I*)%V6@_8=FT3]>:E\;2KD_7R'RPX=+]!YUKOQ!PL-O'TF*
MR,C=SO\`#79N<Z=5#17+,URC.+DJZY1>)=UDZJ[%#J^B'"022&8$)'3'B,I!
MTT2G4^$D\:G+5FU8CR6HI1/)=1U34-6OO(S[L[D^A-^JEPC'<EP^=EK5D-`[
M6)DNWNIG0)4F#,C)<<CRX;[L:0RL(40IIYE2'$'4>`U6D9+EFJQX%8W;EB7?
M692A>C6DHNC7E*X#WE;E;NPMF=QW+Q$3T-IOL)"4W5E/+KFQ?18N`3KJ5(+;
MOD4:OOZ;&7K6*1?!_0;>D^-;UEJQJD7.U]=>TOM+I\GF-P+#D=CRB`BYX_<X
MEU@K`U>BNI6IE9&O9263TO1GAX4K2D^2H>Y;G;ERS33ZST3$S<7/M*_AW(W+
M?4]W4UO3ZG0FZL-H4`H!0"@.*D)6.E0!2>8(!!\X((H"%E6A"R5QE="N)[-6
MI0=>?2KZT^3E0$`ZPZPOLW4*0KQ$<]/"D\B*`ZJ`4`H!0"@%`*`4`H!0"@.2
M4+4H(2E2E*.@2`23KXA0&X.U-G4K#+4Y)/2DOW#[DGWW":\-%*X@5$9?X\O)
M\QW^A_TNWVR^\S+333;*`AI"4)'@2--?*H\U'RGC6L2Q\_OVF?=FN?><[K>2
M6;%A.?S[;69_ZGX1:8C[J6\CG6*WRV;SC;T)*@Q,EW7'Y$@02L%3<U#820%J
MUZSP7K,=&UR%R[3\M>7=R;6V-6N62?0E*BEU-\#P+^Y+X<9/Q'^&F1C:;SRU
MO3I_G,>$6TKKMQDKEIQK24IVG+NJITN*-*59^+;H=X`,22LGI#?JS_:]>O2&
M^RZ.T[7JX=.G5U<--:^C&U1[J'X]\LZ\O++GW4HZUX4IOZC?/,]T<N[JN"X'
MW><*E61&;1%/;J[YN9)B&'YPS8=Q,\L]H39]NK/"S.R7^'8I&$8/"@IO*XK;
M3S]XE/-.J4(J`.5QL*SKF5=U?)4ORTJ6[/+*<.:W"3K<?)*/,IS;<*MTCM6]
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MCS8DME:`MF3$D-*0XDC5*TD5U$9QG!3@TXM5777=3M/$KMJ]CW98]^$[=^$G
M&491:E&46U)-;ZIIIK?54/T5;+=V&Z;"?LBN]/FN6-7&)FV_>U<G-Y]AE+?0
MU8<3B)C,83#7;5'H9NURMDM<Z4LI[4(DM,G[UI7@7CS7+>J:TK&/RO&Q:P4E
M^E+]/;P322[&^D_5[^U+X;97@7X=_P`YU57(:UKDH9,K<FTK5A1:QX\E:*<H
M-W9NG-2<(OV:&X/?/95W>'+7WM[8V^U@6>[#S>[-WG(4*.ZXRU9,CPRY,;'[
MLS&(R%*7(P7.YZ;+,>4E2DVN[CCTMUQ$>#/J`L[;>_H[N2NX[WF,TA7).R>7
M]QO;[NZ[IYI;[;/ND':2_6]5BS[;_+,R9MS$F7;L'OC\N?;I5Q[,LP9'8J>*
M4*"J/I[097[VG>!VL[QFSN2]UWNX9WBN]VZW>&B6_;Z-"VWN<?,;/@&&7RZV
M]69[G;A7RS&59\6QO%L99D/-^M/MR)DLLLL-K6O@2IZSW`QGWL]RSW!]]KSO
M=88LN?9.\5W7;OM7:X;;+SHN?>;V&M[2-BTNM,(7U7/-L;R)5O\`2])PP`-?
M1TJJ7,N%`3M^V=OG="VC[@^Y#-@OV9P^ZK/R-OO$,8Q;)=ZR9RS[^X;)M^[F
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M9/\`TWE9V]C_`*]Z_(<:%L^;^Q:7Z*6D](`K)NM.@%^8SL<]W@=N_P!H1@5G
MN1QS/H??KSS.MI,O2GIDX;N]@V.;;W[;_(FGATN(81>(HB2^E0[2!*?;Y*(H
M]K0/5^S_`-WSWA]VN]WN;*M$C&LHFH[ME@S[%YC#T:1B>YV&[8W/%=Q<7>0Z
MA!Z+5E=KD):5IHI@MJ'OJK))*BX@^F+C+C1Z7$E)\'A!\H/(@U8#KH!0"@/$
MY[]7GH#A0"@,37/^L9_\\D?C%5OP]E=AS5_^)GVOYSPU>8RBE)0E2UJ2A"!U
M+6LA*4I^R4I1`2//1;71;RC:BN:32B8VRK+8CL5^UVQ1?4_HW(EC@PEK7[HT
MR3Z3JEZ:=0T3IKIK6U9L/F4Y>RCG=3U2U.V\;'=6]C?13JXF+JWCFA0"@%`*
M`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('XB;6[I_X[^R_H.9\6_TN/[Y?=D:
MN5,GFI]1>X/^H^X/^;[=_P`#37(^(_Q[?V/^8^@O@Y_2,W_<P^XC?"N=/7Q0
M"@%`*`J.1\WTQ0`\SYS[M`4H!0"@%`*`4!H#WO,CO7^*;'BR;A(:L*,?8NKE
MN:<4W'E3I,^<R7Y:$D)DEIJ*D-A8(1J2!J370Z1;@K$KE$YN=-O0DEN/&OB3
MFY7\PM:>IM8G<J;CT.3E)5?&B226Y;]^TT[J6/-10"@.#OWIW\$[^+555O+9
M^P^QFL"N9]CW!4NCD'O?:7EM[?KMCV88_+M$U^&X_>+9$E-MN*2Q-BR9C,=Z
M-,9!#;[*VG"-%`Z'B-"*Q9$(W;,HS2]E]J)+2,O)Q-0M3QYN,G<BGP:;2::W
M-,^J92>I24@G0G0#B>D$@<O-7*GO35)-+B4((X$$'Q$$'VC504H4%4`H!0"@
M.IUEM]/2ZD*'E`X'Q@\P:`MZ5:'$`KCGM!\&=`L>97)>OMT!#J0I*BDI4%#F
M"""/'J#QX&@.-`*`4`H!0"@%`/;^CZ=`2L6U//@+=!:;/C^^*_@I.G3[-`7%
M'BLQDZ-(T.@!7J>M6GA*N=`;7;9_J7;/YQ<?Z:[4/E_Q#[$=_H?],AVR^\R_
M*UR6*@D$$'0CB".8-`1XM%F"@OYDLG6%=87\SVWK"]>H+ZO5=>L*XZ\]:O[R
MY]:7G?I-;\EA5KW%FO[N'S\I^47]K%W,LJVU[QDW=+;?$<ER7`]^';GF#[.,
MV"[W\XON`V\R<SM4U-JB37(T6\RI*+G$4X$A7K3S:2>QKW/P+XCQ\S25@YER
M$,K&?+64DN:&UPDFVJM+U7UI'Y<_W1_"#4_#GQ"N>)?#^+D9&B:VYY#5JW.[
MW.35?F(2Y%*BG*2NPKT3E']`QG^S<[E68;Z=Y/&Y6XF%Y7CFV6UJX6X>7/9'
MCE[Q]F_2K3<&7,9Q*&[=84+UAR\7IM#DCLBI3<*.Z>!*:W?&/B3'TW1IQP[D
M)YE^MN/+)/E37K2V-[E5+K:X'/?V\?!S5_&OQ$QKVO8>3C^'-+<<J^[MJY:5
MR4))V;$7)1;=RY1SINMPGQ1^PAZUV=]UU]VRV5UUY:W777+1;7''''25.+<6
MJ,5+6M2B23J2:^?E.Y%44I4I3VGZ3]:'AX<I.<K-ES;JWW<*M\7ZO':>I;33
MK:F7667F%I[-;#S+;L=QL:?<UL.)4TIO0`=)'3IX*M-@HZRP^TMB0PQ(CNIZ
M'(\AEI^.X@$$(<CNI6RX@%(]%22.`\5`<DH;0UV"&F41^R[`QTM-ICF/TE!C
ME@)#)CE!T[/IZ-.&FE`>&V6BS61M]FR6:SV1J4OM9+5FM4"TMR7==>TD(M\>
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MYVSQ::;:+[Q`"GGRA*2\\M(`*U:J(`X\!0'!N/&96\XQ%BQW)+G:R7(\9AAR
M4]Q';2G&FT+DO'7WRRI7$\>-`=BT)6DI6D*2>8(H".?@?7,JU\/9JUX>1)H"
M+4E224J!!&H((\7.@*4!XG/?J\]`<*`4!B>Y_P!8S_YY(_&*K?A["[#F;_\`
M$S?15_.6/>LMMEIZFFUB=-&H]784.S;5_P!>_P`4H`\('4KR5L6[,YOA$A\S
M5K&+6$?7O<%N\YBF[9%=+RI7K;W0QKZ$1DJ1'1XM1KJZKRJUK>A9A!;%MXG,
M96=DY;I<E2'!;B#K*:8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('
MXB;6[I_X[^R_H.9\6_TN/[Y?=D:N5,GFI]1>X/\`J/N#_F^W?\#37(^(_P`>
MW]C_`)CZ"^#G](S?]S#[B-\*YT]?%`*`4`H"HY'S?3%`#S/G/NT!2@%`*`4`
MH!0'SE[W?_N3:/\`)]N_XE=ZZ/2/X67[Q_-$\/\`B1_7;?\`MH_?F:KU*'`"
M@%`<'?O3OX)W\6JJK>6S]E]AK/'BR9TEN)"CO2Y3Q"6H\9I;SSATY(;0"H^?
MD*EJQBJS:4>LY2%JY=N*%N+E*3V45>DV'VZV7F&\62YY3(,-+5UMLEJTPU)7
M**FIK#J!,D\6V4A2?20CJ5^^%1N5GP[N4+*JZ/;T>0[?1/"MQ95J_J,N6ER#
MY([77F6][O(?41#+,?J0PTVVC4^\2`3QYD\2HGRDURK;EO/>H6X6ERVTHQ.#
MT=B0DH?:0ZDC3TT@D#]ZKFD^:JIM;BD[<+BY9I-%L3L><2%.05]H.?8.:!8\
MB%\E^8Z&LT;WUB*OZ=**<K&V/![UV<2VU)4VHH<2I"T^^2M)2H><$`UGJGM6
MXC'&47RR7K%*%!0"@%`*`\LB(Q)'W1`ZA[U8X+'D"M#KIY:`MV7:WHX*VP7F
M]2=4`]:1^^1Q/#QB@(LC2@%`*`4`TH#W1K?(D\4IZ6_A%'1)_@_9D#Q4!<46
MW,QNE6G:.`??%@:I/C2.0'B\-`2%`*`VEVS_`%+MG\XN/]-=J'R_XA]B._T/
M^F6^V7WF7Y6N2PH!0'8AUQK7LW%HUTUZ%*3KIRUZ2-:%RE*/LMHJX\ZZ`''%
MK`X@+4I0!X<M2=.5-@E)R]IM^<ZJ%HH!0"@%`*`4`H!0"@%`*`4`H!0'4ZRV
MZDI6D'Q*'!0\QH"*>@N(U4WJM/'APZQYP#Q'EH"$<]^OR*T/D/BH#A0':VRM
MP\!H/LCP'/3GX:`T_P`\R>YOW^^VMMP18D6YS8A$<J2Y(#+[B"MUW@L!?V*=
M!X]:GL:Q%6XSEMDXKR'EFL:CDSS+UB#Y+<;DELZ:/>S'%;:5"!%5`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`Q/O-^J#/]^0/Q$VMW3_QW]E_0<SXM_I<?WR^
M[(U<J9/-3ZB]P?\`4?<'_-]N_P"!IKD?$?X]O['_`#'T%\'/Z1F_[F'W$;X5
MSIZ^*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H!0"@/G+WN_P#W)M'^3[=_Q*[U
MT>D?PLOWC^:)X?\`$C^NV_\`;1^_,U7J4.`%`5`U(`YDZ`>$D\@`.))H$JNB
MWE_6/;RYW5LO7+JM<)QM6G6C^.O)4E0^Y,*T#04#P4YIYC6"YDQM[(JLB<P=
M!R<M=Y?K;L4_XGV+H\I[<<Q*PXK'["S04,K6D!^:Z0]/DGPE^4I(64D_6IZ4
M#P"K;EZY>VW6GU=!*X.FX>G0Y<6%)=,GMD^U_1N+RM?]9VW^?P_Z2W6"?L2^
MR_F)/'_B+?[R/WD;;*]\?.?=J*/0WO*4*"@/++A1IR.F0C50&B'$Z)<;\J5:
M$^QQ%5C.47LW&*[8M7U2XO*MC\Y:4ZQ2HVKC!]99!XZ)T=2-/KVQQ4!XT_N5
ML0NJ6Q[&0]_!N6JRAZUOJW^4A/I<#Y_%64T.FG2*`4`H!0"@(Z5;F9/4K3LW
M#R6GPG3Z]/`*\_.@+=DP'XW%20I'PB-2CV=>*3K[%`>,`\/+X?H\U`=[,5Y]
M82T@JX@%7)"?X2N`!T\'.@+ABVEEG13I[97A21HVD^#0<U<?'0$MH!IH!PY>
M0:::#R4!6@%`*`VEVS_4NV?SBX_TUVH?+_B'V([_`$/^F6^V7WF7Y6N2PH!0
M&O'>:SO<C;#;5S/=NIN$M/V>_8A:[Q;\UQV]WUFX1LSSC%,)BN6YVRY+CJ[>
M_:7,A7*7VG;B0EH-CL]2NJJE=NX'//MU\EVFR'8O&<FLLW/96X$_.K/ES^V&
M$7^[78S,5Q95^AW#%\2CW2[SX=N>DZ)D^L/RNR;X]0)%*=(,2W?O)Y^_W;-I
M-WL>QR*SENY^YMIP==F_P5DN62K5;[IF&9V+M8N!6R^6C(KGD,:WXTT7(?KC
M9;?4[U>BCIHE4&X^/.71^P61^]K9<O+]HM[]T6Q:I=B95/>BM.R>BR3YEPG6
M?1Q9UC/2'G6""A2U$$U0&OVR^ZV=;D[L[UXU>(L2#AVV^X.4X)8Q$V]RN`)_
MS#*LC,>X+W+N%]D8MD%R<;G/>LVZ'`9=C$H)7HE74!";2=X+)=PCW8/G*T8_
M&&]^U&Z>?Y/\V&:HV:XX#<,0@08EG#LM[LX$E[(76Y!?[18=0A(4DZ@@71M1
ME.\=_P!X-U\+S>^[:3L7VUFXA;V?\+87DMDOUV7G.+1\IMTAZ?=,WOL"*BSH
M=5'>0F,HR2D.)4T/1JO0"VML-_\`),Y/=M3<+5CL5>\]MWVF9$B"J:5VIS:>
MXH@6Y%H2[+=*$R%N!,SMPX4KT2GH)TI1@LW:'O*YYN!WBLJVFN-LQY>/6B];
MZ0_XKB688W<[%9MJ,TM&(8_>F,POURDXKN6<FFW)3$^-9V&W;.^$E\I2H!1I
MKL!DK9#=/<+<K-MW8U_@1;=B&#Y_GN#X\F/M[D]I9GC$<OF8[%FL[CW'(YN/
MY7,=C0%KFQ(ENBJBNK`*B$D$^CL!=N\FX&38A(VOQ;#$8Q&RC=O<!6"VG(<U
M1<'\5QKU+%,BS&=,FV^US+;.OEYN$''%Q+5;D2H@ES74]3R4H4E2C8,-7SO#
MY]C&RG>FR2Y6W#[MN1W9[M<L<7=+%"O3N!9K<$XYB>56R=%L:KF]?($^);\M
M;B72T(GO.Q[C'6VB0I*T]-`;+;:7;([[A5GN^6*4;Y-,U<D.8/?]MWD--SI#
M,5N3A>476]7VS2$QVT]0?DK[74.)"4J`H"^J`4`H!0"@*CG[!]PT!;LEE#CK
MFO`AQ?%.@^N//AH>5`="8R$G4ZJ\0/`#S@<Z`]*>8`X`$<!P'M51[@:$9G^M
M^4?W_=/Z6Y72V/P(?97S'CNJ?U+(_?2^<MNLQH"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0&)]YOU09_OR!^(FUNZ?\`CO[+^@YGQ;_2X_OE]V1JY4R>:GU$
M[@_ZC[@_YOMO[MC2*Y'Q'^/;^Q_S'T%\'/Z1F_[F/W$;XUSIZ^*`4`H!0%1R
M/F^F*`'F?.?=H"E`*`4`H!0"@/G5WO674;B6-]3:TL/XC$;8>*%!MYR/<KEV
M[;:M-%+:[9'4.8ZAXZZ/2&GC22Z+C^5+T'B/Q)A..MV9M/DEC*CZ-DI55>.T
MU2/#G]'MU*'GQ==@PZ\7\I<9:]5A$\9TI)2T4@CJ[!O@N0K3['T?&16.Y>A;
M33VLDL'2LO.:G;7+9;]IK93JXF:[#AUGL(2XVUZW.`U5.DI2I:5?[NUQ1'3Y
MM5>6M.Y?G<5-RX([+!T;%PDI+UK_`-9KYET%U+)*5$GZU7[H.OLFL&XE:*C[
M#%_BK96XA62%H0IR[6QM"2I:KA#"4I&I4?6&SP`XG0"K;C2@Z\&9<=-Y-M+:
M^\C\Z-M5>^5YS42>AO8SC52@H!0%02*#IKTD7-M,6=Z13V+Y/!YL`$GE]T3[
MUP>T?+5\;DH]AJW\.U?V^S/BOI1:,VURX)*EH+C/@?:!+?'CHL<2@@<]:V(W
M%/M(:_BW;#K)5AQ1&U>:Y6A04`H!0%-!RT&GBT&A\XY&@/.8D4GJ,=DGQ]FG
MZE`=Z4I0-$I2D>)(`'M#04!RH!0"@%`*`SW8,[P;;_;NSW?/<TQ/![4_-N4>
M/<<OR*TXY"D2!+=46(\B[RXC<AX)()2@J4`==*C[F+DY65*&+;N7)T6R,9/S
MT6SRG5V-;T70M$M9>N9F+A8KG)*=^["U%OF>Q.;BF^I59E6TWBSY!;8=YL%V
MM=]L]P93(@7:RW")=+9.87[UZ)/@NOQ9#9\:%D:UI7+=RU-PO1E":=&I)IKM
M3VHZ+$R\3/QX9>!=M7\2XJQG;G&<)+C&46TUUIGAMN68K>;U?,;M&3X]=<CQ
MA3"<EQ^VWJW3KWCQE`F,+Y:HLEV=:C(`]`/MME7@UJZ=B_;MQO7(3C9G7EDX
MM1E3ZK:H]FW88,?5=+R\N]@8F3CW<_&IWMJ%R$KEJN[O(1;E"O1S)5%SRO%;
M)=;'8;UDV/6>^90\]'QFRW6\VZWW7(I$8-F1'L5OER&I=V?8#J>M$=#BD]0U
M'$4A8OW+<KMN$Y6X>TTFU'KDTJ176Z(KDZIIF'E6,',R;%K.R6U9MSN0C<O-
M;U:A)J5QJJJHIM57$CGY&`;@HR/#I,G$LT38;C;&,NQA<NUWU5CN\&;&OEF8
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M'FE=G.,;:C]9S;45'_4W3K/9MYF6TM]@(QS:G,<`R"W8M;X<<6;!LFL=^;L-
MKU5'@(>CVB?-7!BJ4V4-ES0*((!)K+?P\O%2>3:N6XRW.4913XI52-#2O$7A
M_793AHF?AYD[<4YJQ>MW7%2JHN2A*7*I--)NB='0\<7<'9+%<ENN'Q,]VMQO
M+[KDDFXWK%D9;BUJR.=E]X3&=E2[C957%FXNY!=4)9*BMOMWAT<^%7+`SY6?
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MNVR1N4(=MO>23G&D7)"GDNR7B@.`KZ:/$RU>6/W5SOVJJ/*TVN*35:;]IB_\
MD\._R^YJ_P"?P_Y5:GR3O]];[F$TTN25SFY(RJTN5M.K2I4[TXGLKMC+R/=E
M-IP'`I%\4]<,KS]YZVX_%N3F0SH[\B?>+S)DQ[<IR]W%;2E.K4%2'E).I*N.
M.W:O7[BLVHRE==4DDV]E:[-^RC\QO9>HZ=I^'+4<_(LV-/BDW=N3C"VE)I1;
MG)J*4FTHU>VJIO.SYQV5W[Q^\XTW=-M-X\8:>@*OMH@W7'LUM<.8AU4NTOS&
M[?)G)MUP9?8+L5X%M]M:"MI0*=1DOXN5B-+)MSM.2V<T7&O95+I-72]?T+75
M.6AYN)FJU3G[B];O<E=W-W<I<K='1/?1T+;ML[NRVV`_L%:;OLE"@+D3;%+V
M@C7S#T*D3Y$LR[E;)^)&;ZY-NLN?J[(2\TN2Z^>I?4K4U?\`D<YVOS'<W78:
MKS<DN6G&M*4-=>*?"\M0_E$=2T]ZLI\CL?F+/?*:WP[OGY^9=,:5ZC.;[[;#
M3\F4^VPPPT[)DR)#B6F6&&4*>???=<4EMIIEM*EK4HA*4@DG2M1)MI+:VZ+K
M;V)>4G+DX6H2N76HVX)N3>Q)+:VV]R72WN6^A#8[DV-9A:8]_P`1R*Q9589:
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M>Y<I,9$RXO#WC#94XK0Z`Z5AM8]^_7N(3GRJKY8N5%Q=$Z+K-W4-6TK2E;EJ
MF3CXT;UQ6[;NW(6U.X]T(\[7--]$55O@<H^58M+R2X8;%R;'Y.86B$S<KMBD
M>\V]_)+5;I'9>KS[E9&I"[E!AR.W1T..MI0OK3H>(U=Q>5E9+A-8\G13H^5O
MJ>[90NAJFF7=0N:3:R;$M5M04IV5<@[L(NE)3MI\\8NJHY))U5'M1/5B-XJ.
M?L'W#0$$]]]=_"+^V-`==`*`TKW5L$FQ9A<GG$*]3O3[ET@/Z>@Z)!"I+/4.
M':1Y"B".>A!\-3V'<5RS%5]:*I0\K\0X4\34[DVO=79.47QKO7D?1UF.:W""
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@,3[S?J@S_?D#\1-K=T_\=_9?T',
M^+?Z7']\ONR-7-0.)X`<ZF3S6J6U[C[*=T;;R?@6TT>1>([L.\9E<%Y-)AOI
M*'HD%R.U%M##R%`*;>7":#RDD`CM0#H17#:UE1R,UQ@ZVX+E3^5_*?4/PUT2
M_HWAN,\I..5E3[R2:HU%I*":Z'RJOE-H:B#T`4`H!0"@*CD?-],4`/,^<^[0
M%*`4`H!0"@%`6QE>*8OF-K<M&56J)=82P2TA]&DF,Z1H'X,ILID1'QI[Y"AK
MIQUY5EM7[MF7/;DTS0U#3,#5;'Y;/M1N6NBN]/C%K:GV>4U*N7=GMM@EOW2P
M*E9'%2ZIV-:KF6C+AMCDA"6TH9N2D'D5:*&GO5'C4M'5I75R7$HOC_C<>?7O
MA_CX5QY.*Y9$*U4)TK%=5/;\M&6ZMIQA18<;4PXR>S4PM!;4R4<.@MD)+93I
MIIH-*RUKMWF&G*^5QY9+HI1KJ.%"IQ5[U7\%7VIH'N?80&/X3>;]TO!OU"`?
M_&RD*2'!X?5F?1<?/EX(\M73OP@NLUL32\G+]9KDL_6?3V<3-UAQ.S8^D*BL
M%^9IHJX20E<GB-"&M!T1T'Q)`)\)-:<[L[GM;CI\33L;$VVU6Y]9[_)P\A<M
M8S>%`*`4`H!0`\00>(/,'B#YQX:=F\;]Y!3K#'DDKC'U9T\TI!+*SY4^^02?
M".'DK+"ZX['M1'7]/MSK*UZDOD?H+3DPY,-70^TI&NO2OWS:_P"`L:A7NUL1
ME&6YD3=LW+,N6XFOF/-53$*`4`H!0"@%`*`4`H!0'S@W$E[$X[W\!>N_A;(4
M[8JX[%VR'W=+EN%:[E>=H;5E#,]E>>QYD*/'EVU.1/3DRSU/-J*5+:4H#J84
M.TPXZG<\+NWX8DUJD<EN^H-1NN-%RM-T=*4W;]J3WGS7XDGX)POCF\KXVVHW
M/!5S1H1TJ63"<\&%U23R8N*3AWKFKCK.+HW%O?!GU"[OFY/=;Q3NOWC<CN^0
M8N.=WC`!N;D:66K3><?@$XY,NE\R:=;F<D")[]MNTD%<-XJ+;C+K:$=/3V:.
M+U7"UJ_K4</5'S:K=[N.]2?K445LW-?I+?6K?%_1_@3Q'\,]+^&E[Q%X#C#'
M\`X*S+J]2Y:C[ISNWG%7?6E&<O8G5IJ48JE.5?$[N4[B;@[;]Z+9#O!;C[?;
MBX79>^_=]R\<SG<#+!!9P+.[]N%D#^8;0.X>XU-?FMM6*.PQ#(EM,%Q"RIKJ
M3J1Z-XCP\7,T3)TS$NVKES3HVY0MQ]N$8)0N*7&JJ]GE/C?X-^(=>\/_`!,T
M?QSXAP<_#Q?&5W+LY.3?Y5C9%S+N=_A.PU)R7)ZEM<\8U3;C5-FWG[5#;C)M
MV.\=W#<`P?(E8CN!=W]\)F`Y$A0:7:\WQJTXUE&+.+=U"F8\B^V5AEU8]XAP
MJY`@P7@?+L8.D:GEY,>?%CW2FN,).49?(ZGJO]SWA_4?%'Q"\$:)HM]XNO7/
MYC+&NITY,BS"S?L]B=RW&+?16NZJ<W^R>S[)MT-S._7GF>8X<0SF_;K;=KSO
M&%I+;MFRZV8S>;+DT);2D)<8`O-N?6A!![-*@G4Z:G!X[QK.%B:;B8L^\QHV
M)\DN,7.+3\S53?\`[6]=U+Q)K_C77-<Q_P`IK-[4L7\Q:=?=WX6[D+T=M*+O
M8SHMRK2N\U\M5S[H&*=Y;OS,_M*;+9)>YMVS^7/VSN6Y]BO][M%TV,5!?;Q:
M!M*NWQY*8MP3$[(-F&IM_7H2VXEQMX"7N6]>NZ1ILO"$I+#5I*YW<HIJ]7:[
MM=OD==U>!P6'D_"G3OB'XTM_W#6;4O$<\Z4\2>7;O7(2T[E?<1PN1/EFHTHX
M4EN49*49F_O?`GX)<_V7.[-PVQM[EKVVE=W>R+P6UR+=,M#]NQ1+^.-V2`_;
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MY/+$9+9IUKR)>[3N2?\`J?C`3(M5T8<&+M6KYP,,E#P+G8I=\)37K<)Z2_%^
M)&4<C^;O$CRM-=UR\DFTUOYEMVKBMA^?F3:\?_\`Q[\07+%W25\//_(+JNVY
M0N_GN]_-66G"2]SR5[O?M45))[4?:+]IIT?_`.9VYW6/0_P5LR=-0!^M^`Z=
M))Z=>`TKSOP97_S&RZ[>]O/_`.F9]@?W(4_^.>H[J?E-/_\`S8R./[,>Z;5R
MMOLQ@87?^ZW?,N9?Q&5E1[L6&WK#HD6S.6-,?'V=PFKW'9=NN6-W%JX!<AHE
MHZJT`U-/&<<U9=J63'-C9]91_,2C/UN:LN[:I2%.6D7U;2[^VV_X:N:#EVM(
MO>&KVJJ5B5[^46+EB,;?=N-K\RKBK*_S][ZT6X[TCXJ;\XFY<MV^^!D]XP[!
M+5MM!_:`8E8LZ[QR84NY;M[&MSKN_+8E6")$D0PSA]W3&4F4^MP@3.A/3U*2
MI/HVF9"CIV#8A=N2S):7*4,?=:O-)*DF]\UO2X;:[#XX\<Z3<R/%7BG4LO$P
MK7AZ'CBS;R-52<LW3XRN2ES6XQ:]S-Q:DZ^W14JTU]X?VD>[\O;;NAY5;\)D
M.WK.-\UV#8[;!NUOMR;E?[IN6@VYZ99RTXGU^4YC`DN-J;/2MQULZZ*KR_P?
M@1S=?MO)7+C8U;URJHHJV]B?#UTMF_8S[@_N'\5W/#OPHRL?1Y=]K&MRMZ=A
M\C3G=GE^JY6Z>TW9YG%K>Y1?2:P_LM+Y.VGS[?\`[H&1X1F^U*+&O'MZ=K,`
MW,5;DYA$Q#(;9;[!EI<%KESK;(CN9%!:EH4PZM($E75HH*`F_&]N.=BXOB"W
M=MWW).U=G;KR\Z;<:U2:?*Z;>'8>:_VR:A>\-:WKOPIU##S=,5EVM0P\;,<>
M_5F["-J_7DE*+CWL83]5NG.Z[:I:K]X+N[;@]YKOM]_K;?;3:O:#,KW=+3L-
M%D;D[EWU=DO>RB9.*6-Q&4X0F+!ES;A<;@U#<9DMM=*NS;0-%A729[2]6Q=&
M\.:7EYE^_;MUO^[MQYHW:2?JRZ**O2F>7^./`.N_$?XS^.=`\.Z7I>9F3AIJ
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M0BCZBUQ1]*E1S]@^X:`@GOOKOX1?VQH#KH!0$+?\=L^3P%VV\Q1)8)ZVEI/1
M(BN\NVBO@%3+FG`Z:A0X$$5DM79V9<T-_P`_::F;@XV?9[C*BI0Z.*?%/>F:
MQY?LY?+)VLRQE=^MJ-5J;:;";G&;&I)<CH)3)2D<U->EXTBI>QG6[FRY2,S@
M-2\+Y>'6[B5NX^^GZ:XU73Y##A!25)4%)4E12I*DE*DJ2=%)4E0!2H'@0>5;
MR=54YEIIT=4^O84JI04`H!0"@%`*`4`H!0"@%`*`4!Z(L25.?3&AQW9+ZSHE
MME!6H\-=3I[U(\).B1XZME.,=LMB,ENU=O2Y+47*;Z%_C8NLRC9]M@I`=ODE
M:%D#2'"6D%`/$=M(*5@J\B1[)K1NYM'RV]QT>+X?]7FS)-2^K%KY7M%XVV"6
MR[9)*EK2-3$FJ3JO3P-24A`"B.&BAQ/UPJEO-JZ7-Q3+\/I1YL-MR^J_HE_D
M8)S;;/.<[@QL7QG'ILZ[_/<%Q]"TB-&@QT-2TN2YTU_ICQXK96/2*CU:CI"B
M0#*XV9C8\G>N2I#E?E.*UO0=7U:S'3L&Q.67WJ;3V**Y9>M)O8EUU-AMG.YO
MBN$R(.1Y]*9S+)(RFY,:V(:*,7M<I&BD*[%T!^\/QW!JE;H0UU#4-G@:C\[7
M+M].UC+DLOI_2:^@ZSPQ\+]/TF4,[6)1RLZ.U1I[J,N--\VO]5$GN1ND23SY
M^P/:`Y`"H$]4ZRE`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H"BE)2-5$`#PDZ
M4!X'9AXAH</LR-?_`*0>%`>!2BHZJ))/A/$T!2@+<R#$[)DK>EPBA$E*=&I\
M?1J8W]B"YH0\VG[%8(\U9K=^Y:?JOU>!'YNF8F='WRI=Z)+8UZ3"L_:;(6)@
M:M[L.=#6K5$M3R8RV4D\!(85U*ZD@_[,K!\G*MZ.;::K+8SE[GAS-C<<++C*
MT]S;2\Z,B8]MI9K*CUF?T7BX!"U!;S>D)A703]PBJZ@M23R4YU'P@"M:YE7+
MCY5LA4F\+0L7%CWM[WMZG3[*?4NHMH^UIX.`'#Q```<*S5JC4HEL6XI52@H!
M0"@%`*`4`H!5`<'&T.I*'4)<0>:%CJ2?8/*JIM;MY248S7+-)Q+;FXZ#JY!5
MT\SZNX?1/X-P_N!59H7FMDB+OZ:O:L-TX/Z"UW6G65EMYM32QS2L$'V/`1Y1
MJ*V$T]J(J4)0?+-4D<*%HH!0"@%`*`4`H!0&R>$66RW_`&_M=NO]ELU_MXF3
MWA`OMJM]X@A],U[I?3$N4:5'2\`>"@GJ\M1>1=NVLISM3G"=%MBVG3AL:.UT
M["P=0T:W8S[%F_8YI/EN0A<C7F='RSC)57&E3(;EOMKMO-H=MEN<M!B^HJM#
MD"(NU*A`%(AFV+95!,0)X=EV?9Z>"M53FI]XI25RM>:OK5XUWU)J6-C3Q_RD
M[5N6*X\K@XQ<.7ZO(URTZJ4ZCH>LMDDQH,*39+-)AVMR.]:X<BU6]^):WHB>
MB*];(KL=3%O>BHX-+92A38X)(%7*[=4G-2DIRWM/?V\2R>%A7+<+-VQ9E9M-
M.$7"+4''V7!-4@UT.-&CMD6VVS)<.?,MMNF3[:IU5MGRX$23.MJI`"9"K=,?
M:7)@JD)2`LM*05@:'6J*Y<C%PC)J$MZ3V/M1?/&QKMZ&1=MVYY%NO).48N4*
M[^233<6UL;BU7I*QK;;(,B=+@VRW0I=T>3(N<J'`AQ)-SDI!2)-QD1F&GI\@
M!1T<>4M?$\>-)7+DHJ,Y2E%;JNM.I<$4M8N+8G.[8M6H7;KK.481BYM=,FDN
M9];J^L\EUQ[';ZY">ON.V"^O6U17;GKW9+7=WK>LJZ^N`[<8DER$KJ&NK92>
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M\0V`EM%Z*HI-W0VD:)$GM0D<M*IWUU))3FE'V=K]7LX%SP,"7>5L6/?_`(ON
MX^]IN[RJ]>G1SUIT'NC1HT.,Q#A1HT*)%:2Q&B0V&HL6,PV.EMB/&80VQ'9;
M2-$H0D)`Y`58VY-RDVY/I>\SVK5JQ;5FQ&,+$52,8I*,5P26Q+@E1+@<9<.%
M<(K\&XPH=Q@RFRS)@W",Q-A26E$%34F)*;=CR&B4CT5I*=1RI&4H24H-QDNE
M.C\Y;>LV<FT[&3"%RQ+9*,XJ49+@XR33\J.UAIF*TS'BLM18\9M#,:/&;;CL
M1V6DA+3,=EE*&F&FD@!*4@)2``!H*.3E+FEMD]Y="$+4%;M)1MQBDE%422W)
M);%3@J$5_AS&_F^19_\`#>._,\N0J7+M'S%:OFF7*6XAY<J5;!$$&1*6\VE9
M<6VI94D$G4"LG?WN=7.>7>K9S5=:<$^A&K_+=-_+2P_R^.L2<N9P[JWR.5:\
MSAR\K;>UMQJ^)[9MNMMRAKMUQMMON-M=0VAVVW&#$G6YQ#*D+9;<@RF78CB&
M5MI*`4:)*01IH*LC<N0GWD&U/BFTZ\:K:;%_'Q<FR\?)M6[F.Z5A.,90V;ER
MM.-%T*E#R6O'\>L7;&Q8]8;$9/9^LFQV6V6?UGLNKLO6?FZ+&]8[+K/3U]73
MJ=--:NN7KUVG?3E.FZK;IYVS#BZ?I^!7^7X]C'YJ5[JW"WS4W5Y%%NG14+Q_
M'76KI'=QW'W8]\=#][CNV2UN,7J0DA2)%Y97$+5UD)6D$+D!Q0(U!U`JO?WJ
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M6[T\FW;MQR;E.>:C%2G3=SR2K*G1S-T6Q'K4E*DJ0M*5H6E2%H6`I#C:TE"V
MW$*!2M"TD@@\"*L[#*U&47&23BU1I[J<&>6!;[=:HC4"U6^!:H#'7V$"V0HM
MN@L=:RXL,0X;3,9D+<45'I2-2=3QJZ4YSES7&Y3?2W5OM9BL8^/BVE8Q;<+5
MB.Z,(J,5V1BDEY$>NK3,5'/V#[AH"">^^N_A%_;&@/#+G0K>V'9TN/$0=>DO
MN)1U:`'T4D]2O8!JJC*6R*;9CNWK5E<UV48KK9',9+8)"PVS=X96HZ!*UJ:U
M4?`"ZE"?W:O=JXE5II&"&?AS:4;D*LF^>A'$$:@CB"/&".!%8^TVJ[*E=3SU
M.M"I866;<XYEH6])CF!<R-$72"$MOJ(][ZVWH&IB0>?4`KQ$5LV<J[9V5YH<
M&0^I:'@ZDN:<>2_39*.^O6MTEU?*:PY7MMD>)E;[[!N-K3KTW2"A;C*4Z\/6
MVO2=B+TYE7H:\E&I>SEVKVQ-*7!G`ZEH6=IK<IKO,=?IQW=C6^+XUV&/ZVB$
M%`*`4`H!0"@%`*`4`H#DE"EJ2A"5+6HZ(0E)4I2CR2E*022:HVDJLJHRD^6*
MK)]!D.Q;>SIP;DW9:K=%5HH1P$JG.I.A&J5:HCA0^RU5Y*TKV9&.RWM9.X6A
M7KU+F5ZEKA^D_-N\IEVVVBWVA@1[?&;81H.M6G4\Z1]<\\K[HXKSG0>#2M"=
MZ=SV]YU&/C6,2')CQ45\K[62C;;CJPAI"G%J/!*023[0X#R\JQ&RHRD^6*JV
M7)#Q\^BY.5IX>P;5^XXX/!Y![=6NXDFD2%K!Z;K\B+MA*,,@1M&DI3H$)`""
M!]DGZ[V>-8FV]Y(1C&"Y8I*/47$Q<6G-$NZ-+\!&O9D_PB=4>S5"XD?+X_H]
MF@%`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4!XW9B$<&_34/#]:#_\`E0$>XXMP
MZK43Y/`/,*`ZZ`4`H!0"@.*_>.?@W/M%55;UVELO9?882J06XYE[Q52@H!0"
M@%`*`4`H!0"@%`=$B-'E-]G(:2X..AY+3Y4+'I)(I%RBZIF*[9MWE2XD_G\Y
M:DZP/,:N0R9#7/LCH'D#R:<'!^[Y*V874]DO:^0BK^G3@G*T^:/#I_S+?(()
M!&A2="#P((\!!X@UE(ZC%"@H!0"@%`*`4!M+MG^I=L_G%Q_IKM0^7_$/L1W^
MA_TRWVR^\R_*UR6%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`\LV="MD5
MZ?<9<>!"825/2Y;J&&&TZ'BIQ9`UTY`:D^"KHPE.7+%-R9CNW;5BV[UZ2A:6
M]MT7^.HPW>=R([J5_P"'DB0V_JXU<GT$-J0OTD+C,*"5*!2K4*7IYJVH8S3K
M=\WI(2_KD'%/"]9->TUL[4F8PES)4]Y4B8^[(>6=5..K*CY@#Z*$C7@``!6R
MDHJBV$#<N3NRY[C<I=?T'F^G52PNBRY;=K-TLI<];A<`8<A2B$CC]X=XK9/'
MD-4^2L<[4)K=M-_$U+(Q/57K6OJOZ'T&7;-D]JO8"67NPE::JA2"$/:GX%7O
M'T_P>/DK1G:G;VO<=)C9^/E;(.ESZKW^3CY"X:QFZ.!!20%)4"E25`%*DJ&B
MDJ2>"DD<P>!H'1JC1B#+MGK%?B[-LQ38;HH%12TCJM<EPZ<7HJ?2CJ4>:FM!
MXTFMZQFW+>RYZT/E.9U+PQB9=;N)2SD=7LRKQ71Y*&M&18E?\5DF/>8#K"5$
MAB8V"[!D@'@6921V9)'UIZ5CP@5+6K]N\D[;VG!9NG9>GS[O*CR\'OB^Q^DM
MNLQHB@%`*`4`H!0%"=.-`VEM>XN^Q87=[T$/*1ZA!5Q,F0@A3B?]W9/2MWJ'
M(G1/EK6NY-NWZN^1*8>DY.7ZS7)9XOI[$9ELN,6FQH!BL=I)TT7-?T7(/C[-
M6@#*#XD@>4FHVY?G<V/<=7B:=BX<?=JMQ_I/:_\`(N#GP'$\!P&IU\PYDUAH
MS?["=A6*0_TN228S//I(';+'B"3J$`Z\S5DII;%M9MV<.=SUKFR)=4:+'AHZ
M([:4#ZY1]):_*M9&IK'*3EO)2W:MVE2VJ?.>BK3(<T<_8^F*`[:`]4>8]'/H
MJZD>%M7%/L>(T!-,367]$Z]FYRZ%$<>'UJAP4/:-`>R@%`*`4!4<CYOIB@!Y
MGSGW:`I0"@(^8]R:2>&G4O0^^X\$\#RTH"/H!0"@%`*`4`H#BKWB_*A8_P#L
M-56]=I26V+[#"9&A(/,<ZD%N1S&\I52@H!0"@%`*`4`H!0"@%`*`4!;&0P4A
M`G-`!06EM_\`?!1(0YPX=6HT/C'&LUJ>WE>XBM1L1Y>_BO6K1^7I+4K8(@4`
MH!_TGV!S]J@,59?NYC>,*<AQ5B^W5'HJBP74^K1UZZ$2YR0XTA2=>*$!:_&!
M6Y9P[MW;+U8<?\B#S]?P\*L+?O;ZZ$]B[7_C@,0W;QO)RW$EJ%BNR]$B)->2
M8SZSPZ8DXAMI9/V*PA7BUI>P[MK:O6AU>@:?K^)FM6[GNK[W)O8^I/=YS*OB
M\NFGEUY:>/6M,G=YM/MJA2,,M74".IV>XG4::I7-?Z2/&"!41E_COR'>Z%7^
M66Z\9?>9?5:Q+B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%"0E)6HA*$@J6M
M1`2A*>*E+4>"$I',G@*#KZ#!>;[[8[CA>@X^&\DN[?4A3C+O3:(;@.A#\M&I
ME.(/-#7#]^*D<?3;M[UIOEM_*<CJWB[`PG*QB>_OK97=!<:OI[$:\O-;@[KS
M1.N\MU-M"SV+DA*XUHBI)T4+=`1P?6`??`*)/OEU).>+@1Y;:K<^5]K./C9U
MOQ)>5[)E)6-Z;JH17^F/3V[^LRHK$9=N@Q&XKOK[<>*RTI24%M[[DVE/7V74
ML%)`Y`ZBHY7E-MM4;.K>EW,6Q"-I]Y&,4NO8J;B!(*20H%)!T(4""".8((!%
M7FEN='O*54"@*I44D$<%`@I4"04J'$*20000?#5.W<-VU;R_+'G<^`$1[DDW
M"*G1(=*@F8TGEP</HOA(\"N.GAK!<L1DZQV/Y"7Q=7NV?5O^O;X]*])E>VW>
MW7=GMH$E#VGWQHD)?9)^M=:/I)/'GQ!\!K4G"4'229T5C)LY,>>RZKAT^8DJ
ML,YYY<2+/C.0YT9B7%>!2['DMI>96"-/2;6"G4>`\Q58MQ?-'9(LN6K=Z#MW
MHQE;>]-)KY3`>6;',/%V=B$@1G#U+59IKA,=9'$)ARSJMGAR0YJG]\*DK&H.
M/JWELXKT'&ZCX2A*MW37RO\`Z<MW_"^BG!^<UXN5KN-GEK@W2%(@2V]>IB2V
M6U$`Z=39]ZZ@Z\%))!J4A<A-<T'5'$W\>_BW':R(N%Q=#/!5YA%`*`4`H#+.
MWN/0I$=R]3&4274REL1&G4A;;(9">MXH.J%.J6K0:CT0*C\R\T^ZCPVG3Z%@
MV9VWF7$I2K2-=RIO[69;J.>UG3[R2AVJ5,T4$AIG4:O.`@'^`GWRSI[%6N44
M;%K%NW=M*1Z^DNR';(L+BA':.Z:%YP>G_P#(`=$#S<:Q.<FB3M8UJUM2]?B2
M!.M6FP*`4!S1S]CZ8H#MH!0"@)FW2%J465DJ!05H43KT])`*==>1UH"7H!0"
M@*CD?-],4`/,^<^[0%*`4!#2?O[GG'VHH#HH!0"@%`*`4`H!]'T<J`QS?[([
M%>=EQVU.175%Q70.,=:CZ06`/O95J4GV#6Y:N*2Y>D@\O%E:DYQ5;;^0M:LQ
MI"@%`*`4`H!0"@%`*`4`H!0$7>?ZLE>1+>G_`&S0J^W^(C5SOX2?53Y_\RP:
MVSG10"J@U1WCS;(4Y!<,7C3E0;1%9B=;4/J9>F&3%:D+]:D)(=6V"[H$`A.@
MX@ZU+X./:[M7FDY/<<+X@U'+_-RPX3<<>,55*J<FTGMZNHP+YN%2.U[SF!IK
MPTU\G`_N&E:#?LWHV=[N\_,<HR^U8;ZT[*QZ6F9VTF>%O"U(BQ'9*O5)2SVA
M)#)2&=2./UO.HC4XV+5F60DN\7#I.S\(W=0S-2MZ<I-XTZUYMO+15V/R4H?6
M.%$8M\.+`C([./#8;CLHX:A#20D:D`:J.FI\9-<?*3E)R>]L]_M6H6;<;-OV
M(JB/35ID%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"H!/`4'SF,\VW6Q3"4N,29/
MSG>$CT;-;G&W)"#IP]=>U+,)'$:]1Z].236YCX5[(VI<MOB_HXD%JGB#`TM.
M$GWF2OT(M5_XGNCY:OJ-0,VW8RO-2N/(D_-EG)/19[<MQMA203T^NOZAZ<O3
MGU:(\214WCX=C'VQ5;G%_1P/,]7\1ZAJK=N4N[Q7^A%M)_:Z9>79P1-;6XQ9
M[K&F7:Y1A,>AS1&C,/:*BHT80\75L>]><ZE\.K5(`Y>$:^H7[D)*W!TJJU\I
M*^%M-Q,FU/*R(\TH3Y8I^RMB=:=+,]H]'I2D)2E.@"4@)2E(\``T`2!X*B-^
MU[SO*+8DDDN!,LG[DWI]@C]Q(JY;#,MR(:]6N'*B29"VDID,L.NH>1Z*R6T%
M6CFG!P'I\/&KH2:=.@U,S'LW+<KDDE<C'>8N]WP^?PUM'.(4`H!0'='DR(CR
M)$9YQAYL@I<:64J&G@U!XCR<C5&DU1EUN<[<U.W)QDNE&3;)N$?0CWMK7D!/
M8''Q:R(_`'RJ1IYJU9XRWPW\">Q=9=5;RUL^LOI,FQY,:8RB1$?:D,+`*7&5
MA:3PX@D'5)\8.A%:K33HR>A.%R*G;:<7P.ZJ%Q#WO'[-D<14*]0&)S)UZ%+'
M3(84>'7&DI^[,*'[T^<&K[=R=J7-!T-7+PL;.M=UDP4H?*NQ]!K?EVRMTMH=
MFXRZN\0QJLP'`D71A.O$-]/2U-0D>+I7I];4M9U"$J1N[)<>@X;4O"N1CIWL
M%][:6WE?M+LX_.80<:<9<6T\VXRZVHH<:=0IMQM8YH<;6$K0H>(@5()I[5N.
M3E&4).$TU-;&GL:?6N@X54M%`*H]JH#83;*%)F8\E+#94!/FZN$:-)]-`)4O
MEP\FM1.:UW[;W'<^'+-R]I\5;W<\MO1OXF985DC1M''M)+PT(*DZ-(//T$'7
M4@^$U'N;Z-QUEG#MV_6GZTB9^E5AN"@%`*`4!S1S]CZE`=M`*`4!(VW^4#\$
MO[:@)^@%`*`J.1\WTQ0$B1:-3]TNO,_[&%_W]`4TL_PEU_[&%_W]`-+/\)=?
M^QA?]_0$6^FP]LOJ=O75J->F/`(Y#EK)!Y4!T]./_"WOXO;_`)50#IQ_X6]_
M%[?\JH!TX_\`"WOXO;_E5`.G'_A;W\7M_P`JH!TX_P#"WOXO;_E5`.G'_A;W
M\7M_RJ@'3C_PM[^+V_Y50#IQ_P"%O?Q>W_*J`KTV#0_=;UIH=?XO;O>Z>EK_
M`!K7ITY^"A1TZ=WR>@Q_>T;>E]73(R)$CJ^ZFW0[2XUU<=>M+L]IKK\?0?/6
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M+IGULC]6'[94,[9:C_S+<'\QXQ_J"E;_``AYWZ`XZ93VLC]6'[9J1NC$[OZL
MWNQNU^WM:GEJW=LW;,2V^D0@/4&.R[)V9FL:0HEO3JU0-%:Z:CC4QAO._+QY
M(V>7KE*OR1."UF'AMZC<[^YGJ[2->6W9:]E4HW=3^0Q_ZGW;O_Z+?S_DS;7_
M`%Y6S74?JV/UI_LD9R>%?^KJ/_I6/^\2EHB=V%,QOUZ_;Y.,ZC03,2P!B*%>
M`OJA9K(?4C7P``>/A5EQZER[(V?)*7TQ,MB'A/O5SW-1:KTV[*7EI=;-Q-EV
M-H4YQ8%8Q=-P'G@Q<O46YMAQ&-:%(^;9/:]3UNR.6^@AK4IZ6U:JT!T&IJ%S
MGD_EI=XH4IT.5=_6DCO/"\=&6K67@SR7<]:BE"VH^R][C-O=U=INSTV;X:[?
M%H7RNH`]6'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A
M?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!T
MV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM
M\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\K
MH#&NYC*EV=9M]QS^/;PVOYQ1A]EQN9=U-:'K/:7"_P`&6ECHYB,DKTUU.E;>
M&[?>>LH.==G,VE\B:\Y!Z[',>*^YED1L4]?N8PE.G_%.,J?9VFESD;9OM7.U
MO.[G;=HKM>UQK"NU[7J/5VG7EG:=IU<^KCK4_7+IL5KE[94\GJGEW)HM76YG
M<W3[NU7RUN5\^TZ_5ME_[9W:_P"6L)_U92N7PM>>7[)BY-`_ZF;_`.G:_P"X
M9SVM9VV39[B+3<<^=8^<CVJKI9<:CO!WU1G@VF'?Y+:F^C3B2#KX-*BL_O>]
M7>**?+T-OI?%([CPNM/6%<_*2ON'>[>>,$Z\JW<LI*GE,EAO"]>$S+/S99?%
MQYW;3E6CZW4=+[KC/S+TDC';Q#LAI+RDIU/3U6ZS@Z>Q="--:KZW49EW=/TO
MD])PG-X=ZC,[27E(;]5D=91;K,5A'9*ZB@*NB4E>G+4@:T7-5;MYCO\`==S/
MF<N7EX+TF+BSMQJ?_,<]Y_V-C?Z>K:][PCYWZ#G4L#ZU_P#5A^T4[';C^T<]
M_,V-_IZGO>$?._0*8'UK_P"K#]H=CMQ_:.>_F;&_T]3WO"/G?H%,#ZU_]6'[
M0[';C^T<]_,V-_IZGO>$?._0*8'UK_ZL/VAV.W']HY[^9L;_`$]3WO"/G?H%
M,#ZU_P#5A^T.QVX_M'/?S-C7Z>I[WA'SOT"F!]:]^K#]HN3&V<8]<'S#<=P^
MTU';:6;&_4^CA_*^J_=AT^?TO%QK'=K3WBC3M?H-S"5OO?\`VDLCF^S&GE]:
MAF5*+!TIZY-[*]!U$0K<D%6G$A(N"@./@U-:+I79N.H5:>MO.71CWY1?/B=N
M^74*@(Q_P2+Y\3MW[G\>JCIT@P]NDC9HL$9/)O:;T4?Q95GA6E5]2/K2XD7!
M#*F`?!)(2?`:W\/\U7W7L=>XYCQ#_).3_P#8?Q5-G)3O/+T4^T:Z^K[/?VON
MG_RYAO\`JFI:N3PM^>7H.)Y=%^OE_J6_^X/5]GO[7W4_Y<PW_5-*Y/"WYY>@
M<NB_7R_U+?\`W"<QUG8I-T8-VN.XS\77WMRLV.Q8`7J-#+7;+],F*:\8"0/&
M=*Q7GF<GNU!/J;K\J1M82\.K(7YF62[?^J,5&O7R2E*G8;9PT81ZG&^:)-Q%
ML[)'JGS="LYA]GIP[$M7`)\_A\=04^?F?/7FKMK4].Q^X[E?E>7N.CEI3KW'
MHZ,9_*<@^(VS](U:91T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ
M1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H#L0C&N.DG(/!_P"!M@\?_P"P-`<^
MC&ORF_\`Q*V_+Z`=&-?E-_\`B5M^7T`Z,:_*;_\`$K;\OH#W048]VX[.1?"K
MLU>_AVX)TZN/%,XG6@)GILWPUV^+0OE=`.FS?#7;XM"^5T`Z;-\-=OBT+Y70
1%0FS<?NUVY?DT+QC_>Z`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
